乙酰肝素酶在卵巢上皮癌浸润转移过程中的生物学作用机理研究
|
摘要
卵巢上皮癌是妇科恶性肿瘤中发病率占第三位,死亡率却居第一的恶性疾病。由于卵巢解剖上隐匿于盆腔深处,在发病早期缺乏特异性症状和体征,很难在早期发现和诊断,约60%-70%的卵巢癌患者确诊时己属于晚期。近30年来,虽然经过全世界妇科肿瘤专家的不懈努力,不断改进手术方式,发现更新更好的化疗药物,增加新的化疗方案,但是5年生存率一直徘徊在20%-30%左右。所以,寻找新的诊断方法和新的治疗手段是目前卵巢癌研究的重点。作为一种与粘附和渗出等肿瘤浸润转移必须过程密切相关的物质,乙酰肝素酶(HPSE)在卵巢癌的浸润转移中起着举足轻重的作用。本课题通过一系列体外实验,对HPSE在卵巢癌浸润转移过程中的作用及其机制做了深入的研究,并且构建了HPSE基因慢病毒表达和RNAi载体,为今后的基因靶向治疗奠定了基础。
乙酰肝素酶基因全长扩增和携带其基因的真核表达载体的构建
目的:通过基因工程技术,扩增出乙酰肝素酶基因全长,构建其真核载体。为进一步研究乙酰肝素酶与卵巢癌浸润转移的关系打下基础。方法:选取浆液性卵巢癌组织作为模板提取人卵巢癌组织总mRNA,RT-PCR技术扩增cDNA,利用PCR技术进行乙酰肝素酶基因全长的扩增。将其与真核表达载体pcDNA3.1连接,进行克隆及酶切和测序鉴定。结果:成功扩增出目的基因全长,并经测序验证其同源性达100%。结论:成功从恶性卵巢癌组织中扩增出HPSE全长并构建了其真核表达载体。
乙酰肝素酶介导的卵巢上皮癌细胞系浸润转移体外实验研究
目的:了解乙酰肝素酶对卵巢癌细胞功能的影响,分析HPSE在卵巢癌浸润转移过程中所起的作用;探索其作为早期诊断、治疗靶向的价值。方法:成功构建HPSE基因真核表达载体后,将其转染无HPSE基因表达的卵巢癌细胞株A2780,G418筛选后经RT-PCR及western-blot鉴定确认获得稳定转染的HPSE/A2780细胞株。然后进行细胞生长特性、细胞周期变化、黏附能力、细胞侵袭转移能力的实验。结果:通过转染筛选,获得能够稳定表达HPSE蛋白的卵巢癌细胞株。流式细胞仪对细胞检测结果显示A2780-HPSE组处于增殖状态(S+G2+M)的细胞为46.5%,G1期为53.5%,对照组则相应为54.5%和45.6%,其处于增殖周期的细胞有减少的趋势。HPSE组和对照组的生长曲线几近重合。两组的克隆形成率差异无统计学意义。A2780细胞在转染前后粘附率分别为0.5183±0.0796和0.7283±0.08931,比较有统计学意义(p=0.002)。Transwell小室实验发现转染HPSE基因后的A2780细胞的侵袭能力明显提高,与对照组比较有统计学意义(p=0.003)。而其迁移能力未受影响(p=0.618)。结论:细胞功能实验结果表明,HPSE能够增强卵巢癌A2780细胞的侵袭能力,降低其黏附能力;对增殖能力和迁移能力均无影响。
RNAi阻断乙酰肝素酶介导的卵巢上皮癌细胞系浸润转移体外体实验研究
目的:通过构建人乙酰肝素酶(HPSE)基因的shRNA表达载体,转染卵巢癌细胞,检测其对HPSE基因的干扰效率。继而筛选出稳定干扰的细胞株,进行一系列功能实验,反面验证HPSE基因的功能。方法:针对HPSE mRNA的不同区域构建不同的shRNA表达载体,脂质体法转染HPSE高表达的人卵巢癌细胞系SKOV3,实时定量PCR检验干扰效率,选择抑制率最高的一组细胞进行抗性筛选,获得稳转细胞株,western-blot检验HPSE蛋白受抑制情况,然后进行细胞功能实验。结果:用荧光定量PCR对不同shRNA干扰载体的干扰效果进行检测结果显示,pGPU6/GFP/Neo-HPSE-1222组相对拷贝数为0.936±0.417,与其他3组相比有统计学意义,抑制率为48.63%。获得的该组稳定干扰表达株western-blot检验其HPSE蛋白表达明显减少。细胞生长曲线显示干扰组细胞倍增时间延长。干扰组与对照组集落形成率分别为0.0433±0.0451和0.0397±0.00687,p=0.059,比较无统计学意义。侵袭能力实验中,干扰组吸光值为0.5697±0.106,对照组为0.8097±0.333,干扰组与对照组相比无统计学意义(p=0.233)。细胞粘附能力检测,干扰组0.7533±0.07685,对照组0.5833±0.11994,两者相比有统计学意义(p=0.015)。侵袭能力实验干扰组为0.69±0.085,对照组为1.091±0.277,两者相比有统计学意义(p=0.015)。结论:采用构建shRNA干扰载体对HPSE基因进行干扰,有效地抑制了HPSE基因的活性,使卵巢癌细胞侵袭和黏附能力降低。
HPSE重组慢病毒转基因系统和重组慢病毒干扰系统的构建
目的:采用第二代和第三代慢病毒载体,分别构建HPSE基因的慢病毒表达载体和shRNA慢病毒干扰载体,摸索出较传统转染方法更为高效、可靠的转基因方法,为今后进一步的基因靶向治疗研究打下良好的基础。方法:首先扩增HPSE全长序列,将其与慢病毒载体pWPI连接后测序BLAST检索,并将重组慢病毒质粒转染293T细胞,48小时后提取mRNA,RT-PCR检验HPSE基因表达情况。其次,选取干扰效果最佳的siRNA,设计shRNA结构,退火反应形成双链后与慢病毒载体pSico连接并送测序。结果:重组慢病毒质粒HPSE-pWPI测序结果经BLAST,与HPSE基因的同源性达99%。转染293T后有HPSE基因的表达。重组慢病毒干扰载体pSico/HPSE测序结果与设计的shRNA序列完全一致。结论:成功的构建了HPSE基因的重组慢病毒系统和慢病毒干扰系统。为今后的HPSE靶向治疗奠定了基础。
The morbility of epithelial ovarian is the third in malignant gynecology tumors while the mortality is the first.Ovarian conceals cavum pelvis deeply.On the pathogenetic early stage, deficiency of characteristic symptom and physical symptom make the discovery and diagnosis difficult.About 60-70%of ovarian cancers is advanced stage when they are diagnosed.In recent 30 years,chemotherapeutics modus were discovered,and operandi has been modified.but the 5 years survival rate is just 20-30%.Finding new diagnostic method and therapeutic tool is the focal point in research of ovarian cancer.Heparanase is associative with infiltration of tumor intimately.Heparanase plays an important role in ovarian cancer infiltration too.We discussed the mechanism and effect of heparanase on invasion and metastasis of human epithelial ovarian in vitro.And then we constructed lentivirus expressing vector and RNAi vector of HPSE gene.That can promote the gene targeted therapy. Amplification and eukaryotic vector construction of heparanase gene from
human ovarian cancer tissue
Objective The goal of this study was to amplify the full length of human heparanase gene and construct a eukaryotic vector so as to facilitate the further study.Methods We extracted total RNA from mucus ovarian cancer tissue and then performed reverse transcription polymerase chain reaction to amplify the full length of heparanase gene.The amplicon was then cloned into the vector of pcDNA3.1.The result was confirned by enzyme digestion and sequencing.Results We successfully amplified the full length of human heparanase gene and cloned it into the vector of pcDNA3.1.The homology was 99.9%confirmed by sequencing.Conclusion We successfully amplified the full length of heparanase and cloned it into eukaryotic vector.
Mammalian:heparanase ovarian cancer eukaryotic vector
An in vitro study on heparanase mediated invasive ability of epithelial cancer
Objective:To study heparanase on ovarian function in cancer cells,and analysis its affection on ovarian cancer invasive and metastasis,and pilot its role in early diagnosis, treatment targeting treatment.Method:We successfully constructed HPSE gene expression vector,and transfered it into ovarian cancer cell line A2780,After G418 selection then screening by RT-PCR and western-blot to confirm a stable transfer of the cell lines HPSE/A2780.Then proceed to test the growth of cells,cell cycle,the capacity of adhesion, cell invasion and metastasis experiment.Results:after transfer and screening,we succefully stabilize the protein expression HPSE in ovarian cancer cell line.FCM test showed that A2780-HPSE is in a proliferation of state(S + G2 + M)for 46.5%,G1 for 53.5%, corresponding to the control group,54.5%and 45.6%,respectively.HPSE group and the control group the growth curve almost coincidence.The difference of clone forming unit of the two groups was not statistically significant.A2780 cell adhesion before and after the transfer rate was 0.5183±0.0796 and 0.7283±0.08931,There was significant(p = 0.002). Transwell small room found that gene transfer HPSE after the invasion of A2780 cells markedly improved,compared with the control group were significant(p = 0.003).And its migration were not affected(p = 0.618).Conclusion:cell functions test showed that HPSE can enhance the invasive ability of A2780 ovarian cancer cell,reducing its adhesion ability of the proliferation and migration were not affected.
Mammalian:heparanase transfer ovarian cancer cell functions
Objective:We constructed the expression vector of shRNA and transfer it into ovarian cancer cell lines,then test its interfere rate on HPSE gene function.We also screened some stable transfer cells and did series gene function test.Method:We designed several shRNA vector to inhibit various HPSE mRNA domains and lipofect them into SKOV3,in which HPSE is highly expression.We use real-time PCR to test the interfere rate and we test the antibiotics resistance of the highest interfere group.And we got the stable cell line and did western-blot to test the inhibition of HPSE protein.Results:fluorescence quantitative PCR to test different shRNA interference vector interference effects show that,pGPU6/GFP / Neo-HPSEo1222 goup reative copy number is 0.936±0.417,having statistically significance compared with the other three groups,inhibition rate is 48.63%.The group was stable interfere and western-blot test the expression of HPSE decreased significantly.The cell growth curve showed that cell doubling time extended.Interference group and control group colony-forming rate was 0.0433±0.0451 and 0.0397±0.00687,p = 0.059 and was not statistical significant.In the Invasion experiment,the interference groups adherence value was 0.5697±0.106,the control group was 0.8097±0.333,interference and control group was not significant(p = 0.233).Cell adhesion ability test showed that interference group was 0.7533±0.07685,the control group was 0.5833±0.11994,having statistically significant(p = 0.015). Invasion of interference group was 0.69±0.085,the control group was 1.091±0.277,two groups showed statistically significant(p = 0.015).Conclusion:we successfully constructed shRNA interference HPSE gene vector,effectively curbed HPSE gene activity,reduced the invasion and metastasis ability of ovarian cancer cell.
Mammalian:heparanase RNAi shRNA interference vector cell functions
Objective:Using the second and thkd generation lentivkal vector to construct HPSE expression lentivirus vector and shRNA interference lentivirus vector,exploring a more efficient and reliable method than traditional method of gene transfer,laying a good foundation for further research of targeted therapy.Method:First of all we amplified HPSE full-length sequence,and cloned it into lentiviral vector pWPI and them sequencing,and used BLAST to search the similarity.We transferred reconstruction lentivirus plasmid into 293 T cells,after 48 hours extracted mRNA,RT-PCR test HPSE gene expression.Second,we selected the best interference siRNA,and design shRNA,annealing to a double-stranded and cloned into lentiviral vector pSico then sent to sequencing.Results:BLAST searched the reconstruction of lentivirus vector HPSE-pWPI sequencing results,we found that homology of the vector sequence and HPSE gene is 99%.293 T cell line transfected by HPSE gene can expression HPSE protein.The recombinant of the slow-interference vector pSico / HPSE sequence and the design of shRNA sequence is exactly the same.Conclusion:we successfully constructed the HPSE lentivirus system and the lentivirus interference system laying the foundation for further study of HPSE targeted therapy.
Mammalian:heparanase lentiviralvector transfer siRNA
乙酰肝素酶基因全长扩增和携带其基因的真核表达载体的构建
目的:通过基因工程技术,扩增出乙酰肝素酶基因全长,构建其真核载体。为进一步研究乙酰肝素酶与卵巢癌浸润转移的关系打下基础。方法:选取浆液性卵巢癌组织作为模板提取人卵巢癌组织总mRNA,RT-PCR技术扩增cDNA,利用PCR技术进行乙酰肝素酶基因全长的扩增。将其与真核表达载体pcDNA3.1连接,进行克隆及酶切和测序鉴定。结果:成功扩增出目的基因全长,并经测序验证其同源性达100%。结论:成功从恶性卵巢癌组织中扩增出HPSE全长并构建了其真核表达载体。
乙酰肝素酶介导的卵巢上皮癌细胞系浸润转移体外实验研究
目的:了解乙酰肝素酶对卵巢癌细胞功能的影响,分析HPSE在卵巢癌浸润转移过程中所起的作用;探索其作为早期诊断、治疗靶向的价值。方法:成功构建HPSE基因真核表达载体后,将其转染无HPSE基因表达的卵巢癌细胞株A2780,G418筛选后经RT-PCR及western-blot鉴定确认获得稳定转染的HPSE/A2780细胞株。然后进行细胞生长特性、细胞周期变化、黏附能力、细胞侵袭转移能力的实验。结果:通过转染筛选,获得能够稳定表达HPSE蛋白的卵巢癌细胞株。流式细胞仪对细胞检测结果显示A2780-HPSE组处于增殖状态(S+G2+M)的细胞为46.5%,G1期为53.5%,对照组则相应为54.5%和45.6%,其处于增殖周期的细胞有减少的趋势。HPSE组和对照组的生长曲线几近重合。两组的克隆形成率差异无统计学意义。A2780细胞在转染前后粘附率分别为0.5183±0.0796和0.7283±0.08931,比较有统计学意义(p=0.002)。Transwell小室实验发现转染HPSE基因后的A2780细胞的侵袭能力明显提高,与对照组比较有统计学意义(p=0.003)。而其迁移能力未受影响(p=0.618)。结论:细胞功能实验结果表明,HPSE能够增强卵巢癌A2780细胞的侵袭能力,降低其黏附能力;对增殖能力和迁移能力均无影响。
RNAi阻断乙酰肝素酶介导的卵巢上皮癌细胞系浸润转移体外体实验研究
目的:通过构建人乙酰肝素酶(HPSE)基因的shRNA表达载体,转染卵巢癌细胞,检测其对HPSE基因的干扰效率。继而筛选出稳定干扰的细胞株,进行一系列功能实验,反面验证HPSE基因的功能。方法:针对HPSE mRNA的不同区域构建不同的shRNA表达载体,脂质体法转染HPSE高表达的人卵巢癌细胞系SKOV3,实时定量PCR检验干扰效率,选择抑制率最高的一组细胞进行抗性筛选,获得稳转细胞株,western-blot检验HPSE蛋白受抑制情况,然后进行细胞功能实验。结果:用荧光定量PCR对不同shRNA干扰载体的干扰效果进行检测结果显示,pGPU6/GFP/Neo-HPSE-1222组相对拷贝数为0.936±0.417,与其他3组相比有统计学意义,抑制率为48.63%。获得的该组稳定干扰表达株western-blot检验其HPSE蛋白表达明显减少。细胞生长曲线显示干扰组细胞倍增时间延长。干扰组与对照组集落形成率分别为0.0433±0.0451和0.0397±0.00687,p=0.059,比较无统计学意义。侵袭能力实验中,干扰组吸光值为0.5697±0.106,对照组为0.8097±0.333,干扰组与对照组相比无统计学意义(p=0.233)。细胞粘附能力检测,干扰组0.7533±0.07685,对照组0.5833±0.11994,两者相比有统计学意义(p=0.015)。侵袭能力实验干扰组为0.69±0.085,对照组为1.091±0.277,两者相比有统计学意义(p=0.015)。结论:采用构建shRNA干扰载体对HPSE基因进行干扰,有效地抑制了HPSE基因的活性,使卵巢癌细胞侵袭和黏附能力降低。
HPSE重组慢病毒转基因系统和重组慢病毒干扰系统的构建
目的:采用第二代和第三代慢病毒载体,分别构建HPSE基因的慢病毒表达载体和shRNA慢病毒干扰载体,摸索出较传统转染方法更为高效、可靠的转基因方法,为今后进一步的基因靶向治疗研究打下良好的基础。方法:首先扩增HPSE全长序列,将其与慢病毒载体pWPI连接后测序BLAST检索,并将重组慢病毒质粒转染293T细胞,48小时后提取mRNA,RT-PCR检验HPSE基因表达情况。其次,选取干扰效果最佳的siRNA,设计shRNA结构,退火反应形成双链后与慢病毒载体pSico连接并送测序。结果:重组慢病毒质粒HPSE-pWPI测序结果经BLAST,与HPSE基因的同源性达99%。转染293T后有HPSE基因的表达。重组慢病毒干扰载体pSico/HPSE测序结果与设计的shRNA序列完全一致。结论:成功的构建了HPSE基因的重组慢病毒系统和慢病毒干扰系统。为今后的HPSE靶向治疗奠定了基础。
The morbility of epithelial ovarian is the third in malignant gynecology tumors while the mortality is the first.Ovarian conceals cavum pelvis deeply.On the pathogenetic early stage, deficiency of characteristic symptom and physical symptom make the discovery and diagnosis difficult.About 60-70%of ovarian cancers is advanced stage when they are diagnosed.In recent 30 years,chemotherapeutics modus were discovered,and operandi has been modified.but the 5 years survival rate is just 20-30%.Finding new diagnostic method and therapeutic tool is the focal point in research of ovarian cancer.Heparanase is associative with infiltration of tumor intimately.Heparanase plays an important role in ovarian cancer infiltration too.We discussed the mechanism and effect of heparanase on invasion and metastasis of human epithelial ovarian in vitro.And then we constructed lentivirus expressing vector and RNAi vector of HPSE gene.That can promote the gene targeted therapy. Amplification and eukaryotic vector construction of heparanase gene from
human ovarian cancer tissue
Objective The goal of this study was to amplify the full length of human heparanase gene and construct a eukaryotic vector so as to facilitate the further study.Methods We extracted total RNA from mucus ovarian cancer tissue and then performed reverse transcription polymerase chain reaction to amplify the full length of heparanase gene.The amplicon was then cloned into the vector of pcDNA3.1.The result was confirned by enzyme digestion and sequencing.Results We successfully amplified the full length of human heparanase gene and cloned it into the vector of pcDNA3.1.The homology was 99.9%confirmed by sequencing.Conclusion We successfully amplified the full length of heparanase and cloned it into eukaryotic vector.
Mammalian:heparanase ovarian cancer eukaryotic vector
An in vitro study on heparanase mediated invasive ability of epithelial cancer
Objective:To study heparanase on ovarian function in cancer cells,and analysis its affection on ovarian cancer invasive and metastasis,and pilot its role in early diagnosis, treatment targeting treatment.Method:We successfully constructed HPSE gene expression vector,and transfered it into ovarian cancer cell line A2780,After G418 selection then screening by RT-PCR and western-blot to confirm a stable transfer of the cell lines HPSE/A2780.Then proceed to test the growth of cells,cell cycle,the capacity of adhesion, cell invasion and metastasis experiment.Results:after transfer and screening,we succefully stabilize the protein expression HPSE in ovarian cancer cell line.FCM test showed that A2780-HPSE is in a proliferation of state(S + G2 + M)for 46.5%,G1 for 53.5%, corresponding to the control group,54.5%and 45.6%,respectively.HPSE group and the control group the growth curve almost coincidence.The difference of clone forming unit of the two groups was not statistically significant.A2780 cell adhesion before and after the transfer rate was 0.5183±0.0796 and 0.7283±0.08931,There was significant(p = 0.002). Transwell small room found that gene transfer HPSE after the invasion of A2780 cells markedly improved,compared with the control group were significant(p = 0.003).And its migration were not affected(p = 0.618).Conclusion:cell functions test showed that HPSE can enhance the invasive ability of A2780 ovarian cancer cell,reducing its adhesion ability of the proliferation and migration were not affected.
Mammalian:heparanase transfer ovarian cancer cell functions
Objective:We constructed the expression vector of shRNA and transfer it into ovarian cancer cell lines,then test its interfere rate on HPSE gene function.We also screened some stable transfer cells and did series gene function test.Method:We designed several shRNA vector to inhibit various HPSE mRNA domains and lipofect them into SKOV3,in which HPSE is highly expression.We use real-time PCR to test the interfere rate and we test the antibiotics resistance of the highest interfere group.And we got the stable cell line and did western-blot to test the inhibition of HPSE protein.Results:fluorescence quantitative PCR to test different shRNA interference vector interference effects show that,pGPU6/GFP / Neo-HPSEo1222 goup reative copy number is 0.936±0.417,having statistically significance compared with the other three groups,inhibition rate is 48.63%.The group was stable interfere and western-blot test the expression of HPSE decreased significantly.The cell growth curve showed that cell doubling time extended.Interference group and control group colony-forming rate was 0.0433±0.0451 and 0.0397±0.00687,p = 0.059 and was not statistical significant.In the Invasion experiment,the interference groups adherence value was 0.5697±0.106,the control group was 0.8097±0.333,interference and control group was not significant(p = 0.233).Cell adhesion ability test showed that interference group was 0.7533±0.07685,the control group was 0.5833±0.11994,having statistically significant(p = 0.015). Invasion of interference group was 0.69±0.085,the control group was 1.091±0.277,two groups showed statistically significant(p = 0.015).Conclusion:we successfully constructed shRNA interference HPSE gene vector,effectively curbed HPSE gene activity,reduced the invasion and metastasis ability of ovarian cancer cell.
Mammalian:heparanase RNAi shRNA interference vector cell functions
Objective:Using the second and thkd generation lentivkal vector to construct HPSE expression lentivirus vector and shRNA interference lentivirus vector,exploring a more efficient and reliable method than traditional method of gene transfer,laying a good foundation for further research of targeted therapy.Method:First of all we amplified HPSE full-length sequence,and cloned it into lentiviral vector pWPI and them sequencing,and used BLAST to search the similarity.We transferred reconstruction lentivirus plasmid into 293 T cells,after 48 hours extracted mRNA,RT-PCR test HPSE gene expression.Second,we selected the best interference siRNA,and design shRNA,annealing to a double-stranded and cloned into lentiviral vector pSico then sent to sequencing.Results:BLAST searched the reconstruction of lentivirus vector HPSE-pWPI sequencing results,we found that homology of the vector sequence and HPSE gene is 99%.293 T cell line transfected by HPSE gene can expression HPSE protein.The recombinant of the slow-interference vector pSico / HPSE sequence and the design of shRNA sequence is exactly the same.Conclusion:we successfully constructed the HPSE lentivirus system and the lentivirus interference system laying the foundation for further study of HPSE targeted therapy.
Mammalian:heparanase lentiviralvector transfer siRNA
引文
1.Armstrong DK.Relapsed ovarian cancer:challenges and management strategies for a chronic disease.Oncologist,2002;7Suppl 5:20-28.
2.Fidler IJ:The organ microenvironment andcancer metastasis.Differentiation2002;70:498-505.
3.Fidler IJ:Critical determinants of metastases.Semin Cancer Bio12002;12:89 - 96.
4.Kuwata T,Kitagawa M,Takemura T,etal.Proliferative activity and P53 over-expression of ovarian epithelia tumors.Gen Diagn Pathor,1995:14(2):131-139.
5.Strauli P,Haemmerli G.The role of cancer cell motility in invasion.Cancer Metastasis Rev.1984;3(2):127-141.
6.Volk T,Geiger B,Raz A.Motility and adhesive properties of high- and low-metastatic mufine neoplastic cells.Cancer Res.1984;44(2):811-824.
7.Antoni Castells,Anil K.Rustgi.Tumor Invasion and Metastasis.
8.Li AJ,Madden AC,Cass I,etal.The prognostic significance ofthrombocytosis in epithelial ovarian carcinoma.Gynecol Oncol.2004;92(1):211-214.
9.Nicolson GL.Metastatic tumor cell attachment and invasion assay utilizing vascular endothelial cell monolayers.J Histochem Cytochem.1982;30(3)::214-220.
10.Paget S.The distribution of secondary growths in cancer of the breast[J].Lancet.1889;1:571-573.
11.Rose PG,Piver MS,Tsukada Y,Latus.Metastatic patterns in histologic variants of ovarian cancer.An autopsy study.Cancer 1989;64(7):1508-13.
12.Wu PC,Lang JH,Huang TL,et,al.lymph node metastasis and retroperitoneal lmmphadenectpmy in ovarian cancer.Clin Obstet Gynecol,1989,83(8):1555-1560.
13.Onda T,Yoshikawa H,Yasugi T,etal.Patients with ovarian carcinoma upstaged to stageⅢ after systematic lymphadenctomy have similar survival to Stage Ⅰ/Ⅱ patients and superior survival to other Stage Ⅲ patients.Cancer,1998;83(8):1555-1560.
14.Pereira A,Magrina JF,Rey V,et al.Pelvic and aortic lymph node metastasis in epithelial ovarian cancer.Gynecol Oncol.2007 Jun;105(3):604-8.
15.Canino F.Significance of lymph node sampling in epithelia carcinoma of the ovary.GynecoOnco,1997;65(3):467.
16.吴小华,张志毅,唐美琴.卵巢恶性肿瘤腹膜后淋巴结转移率及危险因素的临床研究[J]。中华妇产科杂志,1996;31:543-547.
17.沈铿,郎景和,连利娟,等.Ⅰ期卵巢上皮性癌全面分期探查术的临床意义[J]。中华妇产科杂志,1996,31(7):390.
18.蒋庆春,来婷。卵巢癌腹膜后淋巴结清除的临床意义[J].中华医学杂志,1998,78(1):77-78.
19.王文福,孙蕊,马玲.晚期卵巢上皮癌腹膜后淋巴结转移清除的合理选择[J].中华妇产科杂志,1999,34(2):108-109.
20.周晖。妇科常见恶性肿瘤的腹膜后淋巴结转移[J].实用癌症杂志,1999,14(2):156-158。
21.黄光琦,贺国丽,宋毅,等.几种肿瘤转移基因变化与卵巢转移的相关性。华西医科大学学报,2002,33(1):28-31.
22.Toh Y,Kunimaks S,Endo K,et al.Molecular analysis of a candidate metastesis-associated,MTA1:posible inferation with histone decay case.Exp Clin Cancer Res,2000,19(1):105.
23.NawaA,Nishimori K,Lin P,et al.Tumer metastasis-associated human MTA1 gene:its deduced protein sequence,localization and associated with breast cancer cell proliferation using antisense phosphorothioate oligonucieotidesl.J Cell Biochem,2000,79(2):202.
24.Tchernitsa OI,Sers C,Zuber J,et al.Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells.Oncogene.2004:23(26):4536-4555.
25.Cautrecasas M,Erill N,Musulen E,et al.K-ras mutations ovarian epithelial tumers:a molecular analysis and clinicopathologic study of 144 patients.Cancer,1998,82(6):1088-1095.
26.Suzuki E,Ota T,Tsukuda K,et al.nm232H1 reduces in vitro cdllmigration and the liver metastatic potential of colon cancer cellsby regulating mypsin lightchain hosp horylation.Int[J].Can2cer,2004,10(8):207.
27.Steeg PS,Bevilacqua G,KooperL,et al.Evidence for a novel gene associated with low tumor metastatic potential[J].J Nail Cancer Imt,1988,80:200.
28.Sadek CM,J imenez A,Damdimopoulos AE,et al.Characterization of human thioredoxin -like 2.A novelmicrotu - bule.binding thioredox2 in expressed p redominantly in thecilia of lung airway epithelium and spermatid manchette and axoneme[J].J Biol Chem,2003,(15):278.
29.温凯辉,温砾,辛晓燕,卢小娟,李青.p53过表达、nm23低表达与卵巢浸润、转移关系的探讨。J Diag Pathol,2005(10):450-452。
30.Kapitanovic S,Spavent iR,Vujsic S,etal.Nm23-H1 gene expression in ovarian tumor potential tumor marker.Anticancer Res,1995,15(2):587
31.Dong J T,Lamb PW,Rinker2Schaeffer CW,et al.KAI1,a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2.Science,1995,268:884-886.
32.Christopher D,Xiao Yu D,J ulie F,et allLoss of expression and altered localization of KAI1 and CD9 protein are associated with epithelialovrian cancer progressionlGynecol Oncol,2002,86:6978
33.宋晖,辛晓燕,肖锋,等1肿瘤转移抑制基因KAI1对卵巢癌细胞增殖及侵袭能力的影响 现代妇产科进展,2003,12(5):3483501.
34.Kareen Blechschrnidt,Elisabeth Kremmer,Regina Hollweck,et al.The E-cadherin Repressor Snail Plays a Role in Tumor Progression of Endometrioid Adenocarcinomas.[J]Diagn Mol Pathol.2007 Dec;16(4):222-228.
35.Bramanandam,Manavathi and Rakesh Kumar.Metastasis Tumor Antigens,an Emerging Family of Multifaceted Master Coregulators[J].Biol.Chem.,Vol.282,Issue 3,1529-1533,January 19,2007
36.Nagfuchi A,Takei M1Cell binding function of E2cad is regulated by the cytoplastic domainlEmbo J,1998,7:367936841.
37.Davidson B,Gotlieb WH,Ber-Baruch G,et al.E-Cadherin complex protein Expression and survival in ovarian carcinoma.Gynecol Oncol.2000,78(3):362-371
38.李晓鸣,朱任之.乳腺髓样癌与粘附因子[J]。中国医学文摘.肿瘤学,2002,16(1):79-81。
39.J Behrens,L Vakaet,R Friis,et al.Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/betaocatenin complex in cells transformed with a temperature-sensitive v-SRC gene.The Journal of Cell Biology,1993;120:757-766.
40.Darai E,Leblane M,Walker CF,et al.Expression of adherins and CD44 isoforms in ovarian endometrial lysts.Human Reproduction.1998,13(5):1346.
41.Loftus J C,Liddington R C.Cell adhesion in vascular biology New insight into integrin-lingand interactinn.J Clin Invest,1997,99(10):2302-2306.
42.F Mitjans,D Sander,J Adan,A Sutt,et al Role of the α_vβ_3 Integrin in Human Melanoma.Cell Invasion.National Academy of Sciences,Vol 89,1557-1561.
43.N Ahmend,F Pansino,Riley Clyde,et al;Overexpression of avβ6 integrin in serious
44.Abe Y,et al.Adefect in cell-to-cell,adhesion viaintegrin- fibronectin interactions in a highly metastatic tumor cellline.[J]Japanese Journal of Cancer Research.1997;88(1):64-71.
45.Sood AK,Coffin JE,Schneider GB,et al;Biological sig-nificance of focal adhesion kinase in ovarian cancer[J][M];Am J Pathol;2004.
46.Sellar GC,Watt KP,Rabiasz GJ,Stronach EA,Li L,Miller EP,et al OPCML at 11q25is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer.Nat Genet 2003:34(3):337-343.
47.姚德生,李力,Kenneth Garson,Barbara C Vanderhyden.OPCML对卵巢癌细胞抑制的体内外实验研究
48.卢建,纪晓峰,江道振,张金山.E-选择素及其配体在人卵巢癌细胞与血管内皮细胞粘附中的作用.中国病理生理杂志,1999,15(11)
49.Schadendorf D,Diehl S,Zuberbier T,et al;Quantitative detection of soluble adhesion in sera of melanoma patients correlates with clinical stage.Dematology 1996,192:89-93.
50.钱思源,王黎娜,刘惠喜.P-选择素在卵巢癌中表达的意义.武警医学,2001,12(9):520.
51.Subramaniam V,Vincent IR,Gardner H,et al.CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation.Exp Mol Pathol.2007 Oct;83(2):207-15.
52.Schroder W,Biesterfeld S Biesterfeld S et al.Expression of CD44(V5 10)splicing variants in primary ovrian cancer and lymph node metastases[J].Anticancer Res,1999,19(5B):3901-3906.
53.Saegusa M,Machida D,Hashimura M,Okayasu I.CD44 expression in benign premalignant,and malignant ovarian neoplasms:relation to tumour development and progression.J Pathol.1999 Nov;189(3):326-37.
54.姚忠强,李力.恶性卵巢肿瘤中CD44V6基因蛋白表达的检测及其意义.肿瘤防治杂志。2000,27(1):4-6.
55.Stickeler E,Vogl FD,Denkinger T,et aloCD44 splice variants and pelvic lymphnode metastasis in ovarian cancer patients[J].Int J Mol Med,2000,6(5):595-601.
56.王忠民,王波,汪洁平,叶萍.血清sCD44v6PCA125检测在卵巢癌患者中的临床应用。中国妇产科临床杂志2003 Nov;14(16)431-435.
57.Folkman J.What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
58.Fidler I J,Ellis L M.The implications of angiogenesis for the biology and therapy of cancer metastasis.Cell,1994,79(2):185-188.
59.Ferrara N.Henzel WJ.Pituitary follicalar cell secrete a novel heparinbonding growth factor specifictor vascular endothelial cell[J].Bio chem Biophys Res lommun,1989,161(2)851.
60.Abu Jawdeh GM,Niloff J,Niloff.Strong expression of vascular permeability factor (vascular endothelial growth factor)and its recptors in ovarian borderline and malignant neoplass.[J]Laboratory Investigation1996,74(6):1105-1115.
61.Michael J.Callahan,John P.Vascular endothelial growth factor(VEGF)and cyclooxygenase 2(COX 2)immunostaining in ovarian cancer Proc Amer Assoc Cancer Res,Volume 452004.
62.Harlozinska A,Kulpa J,Kulpa:Vascular endothelial growth factor(VEGF)concentration in sera and tumor effusions from patients with ovarian carcinoma.Anticancer Research,2004,24(2):1149-1157
63.罗仪,陈双郧,刘永珍等,血管内皮生长因子诊断和监测卵巢恶性肿瘤的临床研究。中国实用妇科与产科杂志,2001年06期
64.DP Barton,A Cai,K Wendt,et al.Angiogenic protein expression in advance epithelial ovarian cancer.Clinical Cancer Research,,Vol 3,Issue 9 1579-1586.
65.Fujimoto J,Ichigo S,etc.Expression of basic fibroblast growth factor and its mRNA in advanced ovarian cancer.Eur J Gynecol Oncol.1997,349-35.
66.王旭平,阎莉荣,毕胜利等,卵巢癌患者围手术期血清bFGF、ColⅣ、HA的变化及 临床意义实用肿瘤学杂志。2007;21(4):316-318.
67.Sakata K,Shigemasa K,Nagai N,et al.Expression of matrix metalloproteinases(MMP2,MMP-9,MT1-MMP)and their inhibitors(TIMP- 1,TIMP- 2)in common epithelial tumors of the ovary.Int J Oncol,2000,17:673-6811.
68.胡晓霞,李力,黎丹戎等,基质金属蛋白酶-2及基质金属蛋白酶组织抑制剂-2在卵巢恶性肿瘤中的表达及其意义。广西医科大学学报,2004,21(5):625-628.
69.Isogai C,Laug W E,Shimada H,et al.Plasminogen activator inhibitor-1 promotes angiogensis by stimulating endothelial cell migration toward fibronectin.Cancer Res,2001,61(14):5587-5594.
70.Hapke S,Kessler H,Arroyo de Prada N,et al.Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.J Biol Chem.2001:276(28):26340-26348.
71.Schmalfeldt B,et al.Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator,its receptor,and inhibitors types 1 and 2.Cancer Res,1995,55(18):3958-3963.
72.梁兰 纤溶酶原激活因子及其抑制因子mRNA表达与卵巢临床病理联系。2004,103-105.
73.SCORILAS A,FOTIOU S,TSIAMBAS E,et al.Determination of cathepsin B expression may offer additional prognostic information for ovarian cancer patients.Biol Chem,2002,383(728):1297-1303.
74.王中显,刘少扬,江大琼.组织蛋白酶B在卵巢癌中的表达及意义.肿瘤,2006 26(6):559-562.
75.Nishida Y,Kohno K,Kawamata T,etc.Increased cathepsin L levels in serum in some patients with ovarian cancer:comparison with CA125 and CA72-4.Gynecol Oncol.1995Mar;56(3):357-361.
76.秦捷。纤溶酶原激活因子及其抑制因子与卵巢癌侵袭转移关系的研究。2007;6:144-148.
77.连利娟.卵巢上皮性癌与交界性瘤的临床[A].见:连利娟 主编.林巧稚妇科肿瘤学[M].第四版.北京:人民卫生出版社.2006,553-554.
78.郎景和,沈铿,向阳.临床妇科肿瘤学[M].北京:人民卫生出版社,2003.290-296.
79.Ali Ayhan,Murat Gultekin,Cagatay Taskiran,et al.Routine Appendectomy in Epithelial Ovarian Carcinoma:Is It Necessary?[J]Obstetrics & Gynecology 2005;105:719-724
80.Parazzini F,Valsecchi G,Bolis G,etal.Pelvic and paraotic lymph nodal status in advanced ovarian cancer and survival.Gynecol Oncol,1999;74(1):7-11.
81.Canino F o Significance of lymph node sampling in epithelia carcinoma of the ovary.Gyneco Onco,1997;65(3):467.
82.Sidmey SC,Louise L.Incidence of paraaortic and pelvic lymph node metastasis in epithelial carcinoma of the ovary.Gynecol Oncol 1983;16:95
83.郎景和。Ⅰ期卵巢癌的淋巴结转移所见:郎景和主编。卵巢肿瘤的基础及临床研究.北京:北京医科大学 中国协和医科大学联合出版社,1996.300-320
84.齐振红,姜玉新,程玉芳,王蕾;超声在早期卵巢癌诊断中的价值.[J]中华超声影像学杂志;2004;5:45-47.
85.林黎娟;卵巢恶性肿瘤的CT表现.[J]中国辐射卫生.2008;17(1):90.
86.罗淑贞,郭友,陈空等;对多排螺旋CT诊断卵巢癌腹膜转移的临床评价。实用医学杂志。2004;20(12):1381-1382.
87.Meyers MA.Distribution of intra-abdominal malignant seeding:dependency on dynamics of flow of ascitic fluid.Am J Roentgenol Readium Ther Nucl Med,1973,119(1):198 -206
87.Coakley FV,Choi PH,Gougoutas CA,et al.Peritoneal metastases:detection with spiral CT in patients with ovarian cancer.Radiology.2002 May;223(2):495-9.
88.吴珊珊,万云,刘波等,卵巢肿瘤的MRI诊断与鉴别诊断.现代临床医学生物工程学杂志.2006;12(2):119-122.
89.朱强等,CT磁共振成像在原发性卵巢癌分期中的应用,中华肿瘤杂志,1999,21(4):296-299.
90.Tempany CM,,Zou KH,,Silverman SG,,et al.Staging of advanced ovarian cancer:comparison of imaging modalities--report from the Radiological Diagnostic Oncology Group.Radiology.2000;215(3):761-767.
91.Kurokawa T,Kawahara K,Kawahara K.Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range.[J]Annals of Nuclear Medicine.2002;16:491-493.
92.Torizuka T,Kanno T,Kanno T.Ovarian cancer recurrence:role of whole-body positron emission tomography using2[fluorine-18]-fluoro-2-deoxy-D-glucose.Eur J Nucl Med Mol Imaging,2002;29(6):797-803.
93.Barranger E,Petegnief Y,Petegnief Y.Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intraoperative probe guidance in a woman with recurrent ovarian cancer.[J]Gynecol Oncol 2005;96:241-244.
94.Rieber A,Stohr I,Stohr I,et al.Preoperative diagnosis of ovarian tumor with MR imaging:comparison with transvaginal sonography,positron emission tomography,and histologic findings.[J].A-J-R 2001;177:123-129.
95.Harpreet K.Pannu,Robert E.Bristow,Christian Cohade,et al.PET-CT in Recurrent Ovarian Cancer:Initial Observations.[J].Radiographics.2004;24:209-223.
96.Smith GT,McDonald T,McDonald T,et al.Cost analysis of FDG PET for managing patients with ovarian cancer.[J].Clin Positron Imaging 1999;2(2):63-70.
97.赵军,管一晖,左传涛等,18F-FDG PET/CT在探测卵巢癌术后复发和转移中的价值。中国肿瘤。2007;3。
98.李春海.肿瘤标志学基础与临床.北京,军事医学科学出版社.2007.10
99.Yang G,Thompson-Lanza,et al.Inhibition of breast and ovarian tumor growth through multiple signaling pathways by retrovirus-mediated siRNA silencing against Her-2/neu gene expression.[J]Journal of Biological Chemistry.2003;18:15-21.
100.Gao D,Lu Y,Lu Y,et al..Significance of HER-2/neu expression in ovarian epithelial tumours.Zhonghua,Bing Li Xue Za Zhi.2002 Jun;31(3):268-70.
101.Alessandra V,Vincenzo C,et al.Suppressive role of metastasis related nm23-H1 gene in human ovarian carcinomas:Association of high messenger RNA expression with lack of lymaph node metastasis.[J]Cancer Research.1995;55:2642.
102.Masaki Mandai,Ikuo Konishi,Masafumi Koshiyama.et al.Expression of Metastasis-related nm23-H1 and nm23-H2 Genes in Ovarian Carcinomas:Correlation with Clinicopathology,EGFR,c-erbB-2,and c-erbB-3 Genes,and Sex Steroid Receptor Expression.Cancer Research.1994,April 1,54:1825-1830.
103.高庆蕾,马丁,孟力等,nm23基因表达与卵巢癌转移的相关性。癌症,2004, 23(6):650-654。
104.温凯辉,温砾,辛晓燕等,p53过表达、nm23低表达与卵巢癌浸润、转移关系的探讨。诊断病理学杂志2005,12:6450-452.
105.Katsuo Morita,Yuko Ono,Hirokazu Fukui.Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors[J].Pathology International.2000 March 3(50):219-223.
106.邬东平,陈惠祯,龚玲玲。卵巢癌p53蛋白表达与细胞增殖状态及预后的关系肿瘤防治研究2003,30(4):294-295。
107.Yin BW,Lloyd KO.Molecular cloning of the CA125 ovarian cancer antigen:identification as a new mucin,MUC16.[J].Biol Chem.2001,Jul,20;276(29):27371-5.
108.Kumar P,Rehani MM,Kumar L,et al.Tumor marker CA-125 as an evaluator and response indicator in ovarian cancer:its quantitative correlation with tumor volume.[J]Med Sci Monit.2005 Feb;11(2):CR84-9.
109.Rustin GJ,Nelstrop AE,Tuxen MK,et al.:Defining progression of ovarian carcinoma during follow-up according to CA 125:a North Thames Ovary Group study.Annals of Oncology 1996,7(4):361-364.
110.Dong L,Cui H,Li XP,et al.Clinical value of serum CA19-9,CA125 and CP2 in mucinous ovarian tumor:a retrospective study of 273 patients.Zhonghua Fu Chan Ke Za Zhi.2008 Jan;43(1):5-8.
111.Kataoka A,Yakushiji M.A study of localizations and serum data;four tumor markers (CA125,CA19-9,CEA and TPA)in ovarian cancers.Nippon Gan Chiryo Gakkai Shi.1990Jan 20;25(1):47-54.
112.Fukatsu T,Nakashima N,Takeuchi J.Diagnosis of ovarian tumor by measuring tumor markers.Rinsho Byori.1992 Feb;40(2):133-8.
113.Dong Y,Kaushal A,Bui L,et al.Human kallikrein 4(KLK4)is highly expressed in serous ovarian carcinomas.Clin Cancer Res.2001 Aug;7(8):2363-71.
114.Ying Dong,Aneel Kaushal,Loan Bui,et al.Human Kallikrein 4(KLK4)Is Highly Expressed in Serous Ovarian Carcinomas.Clinical Cancer Research Vol.2001 August 7:2363-2371,
115.Obiezu CV,Scorilas A,Katsaros D.et al.Higher human kallikrein gene 4(KLK4)expression indicates poor prognosis of ovarian cancer patients.Clin Cancer Reso 2001 Aug;7(8):2380-6.
116.Ying Dong,Aneel Kaushal,Loan Bui,et al.Human Kallikrein 4(KLK4)Is Highly Expressed in Serous Ovarian Carcinomas.Clinical Cancer Research Vol.2001 August 7:2363-2371.
117.Beaufort N,Debela M,Creutzburg S,et al.Interplay of human tissue kallikrein 4(hK4)with the plasminogen activation system:hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor(uPAR).Biol Chem.2006 Feb;387(2):217-22.
118.Prezas P,Arlt MJ,Viktorov P,et al.Overexpression of the human tissue kallikrein genes KLK4,5,6 and 7 increases the malignant phenotype of ovarian cancer ceils.Biol Chem.2006Jun;387(6):807-11.
119.Hoffman BR,Scorilas A,Scorilas A,et al.Immunofluorometric quantitation and histochemical localization of kallikrein 6 protein in ovarian cancer tissue:a new independent unfavourable prognostic biomarker.Br J Cancer 2002;87(7):763-771.
120.曹泽毅 主编.妇科肿瘤学(下篇)[M].第一版.北京:北京出版社,1998,830-838.
121.Brughardt E,Girardi F,Lahousen M,etc.Patterns of pelvic and paraaotic lymph node involvement in ovarian cancer.Gynecol Oncol,1997;40(2):103-106.
122.沈铿,郎景和。妇科肿瘤临床决策。第一版.北京:人民卫生出版社,2007.10,10-11。
123.Bristow RE,Armstrong DK,Armstrong DK,et al.Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era:a meta-analysis.Journal of Clinical Oncology.2002;20(5):1248-1259.
124.李孟达,李玉洁,黄永文,等.影响上皮性卵巢癌远期疗效的因素分析。癌症,2004,23(11):1306-1310.
125.Onda T,yashikawa H,Yasugi T,et al.Assessment of metastases to aortic and pelvic lymph nodes in eptithelial ovarian cancer.[J]Cancer.1996;78:903-908.
126.缪智辉,殷平等,卵巢癌患者大网膜切除的临床病理分析。2001,23(6):650-654。
127.E S Bamberger and C W Perrett.Angiogenesis in epithelian ovarian cancer.[J]Mol.Pathol.Dec 2002;55:348-359.
128.YF Shi and YP Cheng.Zhonghua Fu Chan Ke Za Zhi,March 1,1990;25(2):70-2,
129.EW Munnell.The changing prognosis and treatment in cancer of the ovary.A report of 235 patients with primary ovarian carcinoma 1952-1961.[J]Am J Obstet Gynecol,Mar 1968;100(6):790-805.
131.Parker R T.Cancer of the ovary survival study based upon operation therapy chemotherapy and radiotherapy.Am J Obstet Gynecol,1970,188;878.
132.姚德生,李力。卵巢上皮性癌手术治疗现状。[J]浙江肿瘤。2000,6(4):241-245。
133.Wu PC,Huang RL,Huang RL,et al.Lymph node metastasis and retropcritoneal lymphadennectomy in ovarian cancer.[J]Baillier's Clinical Obstetrics and Gynaecologyo 1989;3:143.
134.P Morice,F Joulie,S Camatte,et al.Lymph node involvement in epithelial ovarian cancer:analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications.J Am Coll Surg,August 1,2003;197(2):198-205.
135.吴小华,张志毅,唐美英,等.卵巢恶性肿瘤的腹膜后淋巴转移率及危险因素的临床研究[J]中华妇产科杂志,1996,31(9):543-547.
136.JK Chan,R Urban,JM Hu,et al.The potential therapeutic role of lymph node resection in epithelial ovarian cancer:a study of 13918 patients.Br J Cancer,June 18,2007;96(12):1817-22.
137.Di Re F.Value of lymph node assessment in ovarian cancer:Status of the art at the end of the second millennium.[J]International Journal of Gynecological Cancer.2000;10(6):435-442.
138.M Suzuki,M Ohwada,T Yamada,et al.Lymph node metastasis in stage I epithelial ovarian cancer.[J]Gynecol Oncol,November l,2000;79(2):305-8.
139.Faught W,Le T,Fung Kee Fung M,et al.Early ovarian cancer:what is the staging impact of retroperitoneal node sampling?[J]Obstet Gynaecol Can.2003 Jan;25(1):18-21.
140.Stratton JF,Tidy JA,Paterson MEL.The surgical management of ovarian cancer.Cancer Treat Rev,2001,27(2):111-118.
141.Di Re F,Raspagliesi F,et al.Pelvic and paraaortic lymphadenectomy in cancer of the ovary.[J]Clinical Obstetrics and Gynaecology.1989;3(1):131-142.
142.D Guthrie,ML Davy,and PR Philips A study of 656 patients with "early" ovarian cancer.[J]Gynecol Oncol,Mar 1984;17(3):363-9.
143.Yokoyama Y,Sato S,Sato S,et al.Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer.[J]European Journal of gynaecological oncology.1999;20,5-6:361-366.
144.Poncheville L,Lefrancq T,Lefrancq T,et al.Does paraaortic lymphadenectomy have a benefit in the treatment of ovarian cancer that is apparently confined to the ovaries?[J]Eur J Cancer.2001;37:210-215.
145.余冬青,李力。卵巢上皮性癌腹膜后淋巴结清扫的临床价值[A];中华医学会第九次全国妇科肿瘤学术会议论文汇编[C];2006年。
146.EISENKOP S M,SPIRTOS N M.The clinical si fi eanee of occult maeroscopieally positive retroperitoneal nodes in patients with epithelial ovarian eancer[J].Gyneeol Oncol,2001,82:143-149
147.P_Benedetti Panici,G Perniola,R Angioli,et al.Bulky lymph node resection in patients with recurrent epithelial ovarian cancer:impact of surgery.Int J Gynecol Cancer,November 1,2007;17(6):1245-51.
148._赵晶,刘新民。卵巢恶性肿瘤手术同时切除阑尾53例分析(J)现代妇产科进展,1996,5(1):38-40。
149.张亦文,刘新民,孙玉蓉.妇科手术同时切除阑尾的探讨[J].中国实用妇科与产科杂志,2001,17(3):165。
150.李力.卵巢癌阑尾切除临床分析[J].临床外科杂志,2001,1,9.
151.Westermann G,Mann WJ,Chumas J,etc.Routine appendectomy in extensive gynecologic operation.Surg Gynecol Obsted,1986,162:307.
152.Ayhan A,A1 RA,Baykal C,etc.The influence of splenic metastases on survival in FIGO stage ⅢC epithelial ovarian cancer[J].Int J Gynecol Cancer,2004,14(1):51- 56.
153.Pedro T.Ramireza,Brian M.Slomovitza,Lacey McOuinnb,et al.Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer.[J]Gynecol Oncol.2006 Dec;103(3):888-90.
154.Malfetano JH.The appendix and its metastatic potential in epithelial ovarian cancer.Obstet Gynecol,1987,69:396.
155.Fontanclli R,Paladini D,Raspagliesi F,etc.The role of appendectory in surgical procedures for ovarian cancer.Gynecol Oncol,1992,46:42-43.
156.Natalina Manci,Filippo Bellati,Ludovico Muzii,et al.Splenectomy During Secondary Cytoreduction for Ovarian Cancer Disease Recurrence:Surgical and Survival Data.[J]Annals of Surgical Oncology 13:1717-1723(2006).
157.T Bilgin,K Ozerkan,and H Ozan.Splenectomy in cytoreductive surgery for advanced ovarian cancer.[J]Arch Gynecol Obstet,April 1,2005;271(4):329-31.
158.LM Chen,RS Leuchter,LD Lagasse,and BY Karlan.Splenectomy and surgical cytoreduction for ovarian cancer.[J]Gynecol Oncol,June 1,2000;77(3):362-8.
159.SM Eisenkop,NM Spirtos,and WC Lin.Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer.[J]Gynecol Oncol,February 1,2006;100(2):344-8.
160.PM Magtibay,PB Adams,MB Silverman,et al.Splenectomy as part of cytoreductive surgery in ovarian cancer.[J]Gynecol Oncol,August 1,2006;102(2):369-74.
161.A Ayhan,RA Al,C Baykal,et al.The influence of splenic metastases on survival in FIGO stage ⅢC epithelial ovarian cancer.[J]Int J Gynecol Cancer,January 1,2004;14(1):51-6.
162.W Cliby,S Dowdy,SS Feitoza,et al.Diaphragm resection for ovarian cancer:technique and short-term complications.[J]Gynecol Oncol,September 1,2004;94(3):655-60.
163.DF Silver.Full-thickness diaphragmatic resection with simple and secure closure to accomplish complete cytoreductive surgery for patients with ovarian cancer.[J]Gynecol Oncol,November 1,2004;95(2):384-7.
164.GD Aletti,SC Dowdy,KC Podratz,et al.Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer.[J]Gynecol Oncol,February 1,2006;100(2):283-7.
165.杨来春,段涛,朱关珍.铁林迪妇科手术学[M].济南:山东科学技术出版社,2003.1453-1463.
166.张师前,智绪亭,李家福。晚期卵巢癌理想肿瘤细胞减灭术可行性研究[J]。中国现代手术学杂志,2004,8(6):345-347。
167.Cai HB,Zhou YF,Chen HZ.et al.The role of bowel surgery with cytoreduction for epithelial ovarian cancer.[J]Clin Oncol(R Coll Radiol).2007 Dec;19(10)757-62.
168.S Abdul et al.Can we identify the patients likely to undergo bowel resection at the time of operation for ovarian cancer?[J]Obstetrics and Gynaecology;May 2006,26(4),357-62.
169.Ritu Salania,Marianna L.Zahurakb,et al.Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer:A case-control study.[J]Gynecologic Oncology.2007;107(3):495-499.
170.Tien Le,FRCSC,Ghadeer Alshaikh,et al.Prognostic Significance of Postoperative Morbidities in Patients With Advanced Epithelial Ovarian Cancer Treated With Neoadjuvant Chemotherapy and Delayed Primary Surgical Debulking.[J]Annals of Surgical Oncology 2006;13:1711-1716.
171.Steed H,Oza AM,Murphy J,et al.A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer.[J]International Journal of Gynecological Cancer.2006 February;16(1):47-53.
172.王世阆等,卵巢疾病,人民卫生出版社[M],2004.1:237.
173.Ozols RF,Btmdy BN,GreerBE,et al.Phase Ⅲ trial of calboplatin and paclitaxel compared with cisplatin and paclitaxd in patients with optimally resected stage Ⅲ ovarian Cancer:a Gynecology Oncoloy Group study[J].Clin Oncol,2003,21(17):3194-3200.
174.S.W.Hansen.Gemcitabine in the treatment of ovarian cancer.International.[J]Journal of Gynecological CancerVolume.2001 July;11(1):39-41.
175.Muggia F.Phase Ⅲ data on Caelyx in ovarian cancer.[J]European Journal of Cancer.2001;37:15-18.
176.McGuire WP,Hoskins WJ,Brady MF,et al.Cyclophosphamide and cisplatin versus paclitaxel and cisplatin:a phase Ⅲ randomized trial in patients with suboptimal stage Ⅲ/Ⅳovarian cancer(from the Gynecologic Oncology Group).Semin Oncol.1996 Oct;23(5 Suppl 12):40-7.
177.J.TateThigpen.Multi-Center 5-Arm Randomized Trial of Initial Chemotherapy for Advanced Ovarian Cancer
178.Muggia FM,Brady MF,Brady MF,et al.Phase Ⅲ randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage Ⅲ or Ⅳ ovarian cancer:a gynecologic oncology group study.[J]Journal of Clinical Oncology.2000;18(1):106-115.
179.李君凤.TPC化疗方案治疗晚期卵巢癌的疗效观察.临床和实验医学杂志。2007;6(2):56-58。
180.刘俊宝,冷维春,张爱臣等,TP及CAP化疗方案治疗晚期卵巢癌的比较。[J]中华现代妇产科学杂志.2005;2(2):110-112。
181.Armstrong DK,Bundy B,Wenzel L,et al.Intraperitoneal cisplatin and paclitaxel in ovarian cancer.[J]N Engl J Med 2006;354:34-43.
182.Piccart MJ,Gore M,Ten Bokkel Huinink W,et al.Docetaxel:An active new drug for treatment of advanced epithelial ovarian cancer.[J]Natl Gancer Inst,1995,87:676-681.
183.du Bois A,Luck HJ,Meier W,etc.A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.J Natl Cancer Inst.2003Sep3;95(17):1320-9.
184.Vasey PA,Jayson GC,Gordon A,etc.Phase Ⅲ randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.J Natl Cancer Inst.2004 Nov 17;96(22):1682-91.
185.Mori T,Hosokawa K,Kinoshita Y.etc.A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer._Int J Clin Oncol.2007 Jun;12(3):205-11.Epub 2007 Jun 27.
186.Andreas du Bois,Hans-Joachim Luck,Weaner Meier,et al.A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer.JNCI Journal of the National Cancer Institute 2003 95(17):1320-1329.
187.Pfisterer J,Weber B,Reuss A,etc.Randomized phase Ⅲ trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer:a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.J Natl Cancer Inst.2006 Aug 2;98(15):1024-6.
188.Mauricio Cuello,Seth A.Ettenberg,Amy So Clark,et al.Down-Regulation of the erbB-2Receptor by Trastuzumab(Herceptin)Enhances Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated Apoptosis in Breast and Ovarian Cancer Cell Lines that Overexpress erbB-2.[J]Cancer Research 61,4892-4900,June 15,2001.
189.Michael A.Bookman,Kathleen M.et al.Evaluation of Monoclonal Humanized Anti-HER2 Antibody,Trastuzumab,in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2:A Phase Ⅱ Trial of the Gynecologic Oncology Group.[J]Journal of Clinical Oncology,Vol 21,Issue 2(January),2003:283-290.
190.S.Makhija,D.Glenn,F.Ueland,M.et al.Results from a phase Ⅱ randomized,placebo-controlled,double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian,fallopian tube,or primary peritoneal cancer.Journal of Clinical Oncology,2007 ASCO Annual Meeting Proceedings Part Ⅰ.Vol 25,No.18S(June 20 Supplement),2007:55
191.Berek JS,Schultes BC,Nicodemus CF.Biologic and immunologic therapies for ovarian cancer.[J]Clin Oncol.:2003 May 15;21(10 Suppl):168s-174s
192.Thomas G Ehlen,Alan N Gordon,Howard J Fingert,et al.Adjuvant treatment with monoclonal antibody,OvaRex MAb-B43.13(OV)targeting CA125,induces robust immune responses associated with prolonged time to relapse(TTR)in a randomized,placebo-controlled study in patients(pts)with advanced epithelial ovarian cancer(EOC).2002 ASCO Annual Meeting.
193.Deborah K.Armstrong,John A.Blessing,Katherine Y.Look,et al.A randomized phase Ⅱ evaluation of bryostatin-1(NSC #339555)in recurrent or persistent platinum-sensitive ovarian cancer:A Gynecologic Oncology Group Study.[J]Investigational New Drugs.2003August;21(3):373-377.
194.Hu L,Mills GB,Mills GB,et al.In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor(LY294002).[J]Clinical Cancer Research.2006;6(3):880-886.
195.Sewell JM,Ritchie A,Ritchie A,et al.Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839("Iressa").[J]Br J Cancer.2002 86:456-462.
196.Russell J.Schilder,Michael W.Sill,Xiaowei Chen,et al.Phase Ⅱ Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression:A Gynecologic Oncology Group Study.[J]Clinical Cancer Research Vol.11,5539-5548,August 1,2005.
197.Wagner U,du Bois A,Pfisterer J,et al.Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase Ⅱ trial of the AGO Ovarian Cancer Study Group(AGO-OVAR 2.6).Gynecol Oncol.2007Apr;105(1):132-7.
198.Alberts.Liu,wilczynski,jang,et al.Phase Ⅱ trial of imatinib mesylate in recurrent,biomarker positive,ovarian cancer(Southwest Oncology Group Protocol S0211)[J]International Journal of Gynecological Cancer.August 2007;17(4):784-788(5).
199.D.Wright,A.Alvarezsecord,T.M.Numnum,et al.A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent,platinum-resistant ovarian cancer.[J]Journal of Clinical Oncology,2006 ASCO Annual Meeting Proceedings Part Ⅰ.Vol 24,No.18S(June 20 Supplement),2006:5019.200.Chura JC,Van Iseghem K,Downs LS Jr,et al.Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.Gynecol Oncol.2007 Nov;107(2):326-30.Epub 2007 Aug 15.
201.Hirte H,Vergote IB,Jeffrey JR,et al.A phase Ⅲ randomized trial of BAY 12-9566(tanomastat)as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy:a National Cancer Institute of Canada Clinical Trials Group Study.Gynecol Oncol.2006 Aug;102(2):300-8.
202.Michael J,Mohammad A,Anil K,et al.Ovarian Cancer p53 Mutation Is Associated with Tumor Microvessel Density.[J]Gynecologic Oncology.July 2002;86(1):85-90.
203.Zhang T,Guan M,Jin HY,etc.Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.Gynecol Oncol,2005,97(2):501-507
204.Thomas G,Robert F,Abbas Abdollahi,etc.The biology of ovarian cancer.Fox Chase Cancer Center 2001 Scientific Report.
205.Tanyi JL,Lapushin R,Eder A,etc.Identification of tissue-and cancer-selective promoters for the introduction of genes into human ovarian cancer cells.Gynecol Oncol,2002,85(3):451-458.
206.Kong BH,Song Y,Ma DK,etc.In vitro treatment of ovarian cancer cells with cytonine dearnases-thymidine kinase fusion disuicide gene therapy system under the control og human telommase reverse transcriptase gene promoter.Zhonghua Fu Chan Ke Za Zhi,2004,39(6):390-395.
207.Wen SF,Mc Donald,et al.Mevelopment and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.[J]Cancer Gene Ther.2000;7:1469-1480.
208.Alvarez RD,Gomez-Navarroj,Wang M,etc.Adenoviralmediated suicide gene therapy for ovariancancer[J].Mol Ther,2000,2(15):524-530.
209.Hook M,Irimutra T,Nicolson GL,A heparin sulfate-dagrading endogly considass from rat liver tissueo[J]Biochem Biophys Res Commun.1975,67:1422.
210.Vlodavsky I,Friedmarm Y,Elkin M,et al.Mammalian heparanase:gene cloning,expression an d function in tumor progression and metastasis.Nat Med,1999,5(7):793-802.
211.Hulett MD,Freenmn C,HamdoH BJ,et al.Cloning of mammalian heparanase,an importan t enzyme in tumor invasion an d metastasis,Nat Med,1999,5(7):803-809.
212.Fairbanks MB,Mildner AM,Leone jw,et al.Processing of thehuman heparan ase precursor an d evidence that the active enzyrne is a heterodimer.J BiOl Chem,1999,274(42):29587.29590.
213.Gohji K,Katsuoka Y,Okamoto M,et al.Human heparanase:roles in invasion and metastasis of cancer[J].Hinyokika Kiyo,2000,46(10):757-762
214.Vaday GG,Lider O.Extraeellular matrix moieties,cytokines,and enzymes dynamic effects on immune cell behavior and in--flammation.[J]LeukBiol.2000.67(2):149-158.
215.Eccles SA.Heparanase:breaking down barriers in tumors.[J]Nat Med,1999;5(7):735-736.
216.Gilat D,Hershkoviz R,Goldkorn I,et al.Molecular behavior dapts to context:heparanase functions as fin extracellular matrixdegrading enzyme or as fl T cell adhesion molecule,depending onthe local pH.[J],.J Exp Med,1995,181(5):1929.
217.Ihrcke NS,Reissner KJ,Reissner KJ,et al.Regulation of platelet heparanase during inflammation:role of pH and proteinases.[J]Journal of Cellular Physiology.1998;175:255-267.
218.Vlodavsky I,Friedman Y.Molecular properties and involvement of heparanase in cancer metastasis and mlgiogenesis[J].J Clin Invest.2001.108:341
219.Eccles SA.Heparanase:breaking down barriers in tumors[J].Nat Med,1999,5(7);735.
220.Pillarisetti S.lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan)and atherogenicity[J].Trends Cardiovasc Med,2000,10(2):60-65.
221.Marchetti D,Li J,Shen R.Astrocytes contribute to the brain metastatic specificity of melanoma cells by producing heparanase.Cancer Res,2000,60(17):4767-4770.
222.Sasaki M,Ito T.Erythromycin and clarithromycin modulation of growth factor-induced expression of heparan ase mRNA on human lung cancer ceils in vitro[J].Mediators Inflamm,2001,1of5):259.
223.Walch ET,Marchetti D.Role of neurotrophins and neurotrophins receptors in the in vitro invasion and heparanase production of human prostate cancer cells[J].Clin Exp Metastasis,1999,17(4):307.
224.Shteper P J,Zcharia E,Ashhab Y,et al.Role of promoter methylation in regulation of the mammalian heparanase gene.Oncogene,2003,22(49):7737-7749.
225.Oqishima T,Breault JE,Breault JE,et al.Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer.[J]Oncogene.2005;78(5):667-674.
226.de MestreA M,KhachigianLM,Santiago F S,et al.Regu lation of inducible heparanase gene tran scription in activated T cells by early growth response[J]Biol Chem,2003,278(50):50377-50385.
227.Ogishima T,Shiina H,Breault J E,et al.Increased heparanase expression is caused by promoter hypomethylation an dup-regu lation of transcriptional factor early growt h response.[J]irIham anprostate cancer.ClinCancerRes,2005,11(3):1028-1036.
228.Irit Cohen,Bella Maly,Itamar Simon,et al.Tamoxifen Induces Heparanase Expression in Estrogen Receptor-Positive Breast Cancer.[J]Clinical CancerResearch.2007.July 15;3:4069-4077.
229.Gingis-Velitski S,Zetser A,Kaplan V,et ol.Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans.[J]BiolChem,2004,279(42):44084-44092.
230.Michael Elkin,Irit Cohen,Eyal Zcharia,et al.Regulation of Heparanase Gene Expression by Estrogen in Breast Cancer.Cancer Research 63,8821-8826,December 15,2003.
231.Goldshmidt O,Zcharia E,Cohen M,etc.Heparanase mediates cell adhesion independent of its enzymatic activity.FASEB J,2003,17(9):1015-1025.
232.Friedmann Y,Vlodavsky I,Aingorn H,et al.Expression ofheparanase in normal, dysplastic and neoplastic humancolon mucosaalld stroma[j].Am JPathol,2000,157:1167.
233.Osama N,El-Assal Akira Yamanoi,Takashi Ono,et al.The Clinicopathological Significance of Heparanase and Basic Fibroblast Growth Factor Expressions in Hepatocellular Carcinoma.Clinical Cancer Research Vol.7,1299-1305,May 2001.
234.Alexander Koliopanos,Helmut Friess,Jorg Kleeff,et al.Heparanase Expression in Primary and Metastatic Pancreatic Cancer.Cancer Research 61,4655-4659,June 15,2001.
235.王辉,王谦。宫颈癌组织中乙酰肝素酶表达的临床研究。黑龙江医学。2007年04期。
236.Vlodavsky I,Zcharia E,Goldshmidt O,etc.Involvement of heparanase in tumor progression and normal differentiation.Pathoph3 siol Haemost Thromb,2003;3:[Suppll]:59-61.
237.崔红梅,王海琳,乙酰肝素酶在妇科肿瘤中的研究进展,国外医学妇产科学分册,2005,32(6):371-373。
238.ParishCR,Freeman C,Brown KJ,,et al.dentification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.Cancer Res,1999;59(14):3433-3441.
239.Kodama J,Hashen G,Hashen GH,et al.eparanase messenger RNA expression in epithelial ovarian tumor.[J]Int J Mol Med.2003;12(6):961-964.
240.Davidson B,Shafat I,Risberg B,etc.Heparanase expression correlates with poor survival in metastatic ovarian carcinoma.Gynecol Oncol.2007 Feb;104(2):311-9.Epub 2006 Oct 9.
241.毛敬,辛晓燕,刘玉等,卵巢癌uPA及HPA的表达与肿瘤转移的相关性研究,现代肿瘤医学,2006,3,14(3):329-331.
242.韦露薇,李力。乙酰肝素酶与卵巢癌浸润转移关系的相关研究。2008年3月硕士学位论文。
243.黄庆,田辉,李林等,乙酰肝素酶与肿瘤关系的研究进展,现代诊断与治疗,2006,5,17(3):160-163
244.Ginath S,Menezer J,Friedmann Y,et al..Expression of heparanase,Mdm2,and erbB2in ovarian cancerolnt J Oncol,2001,18(6):1133-1144.
245.韩静,杨鹰,阎萍等,乙酰肝素酶在卵巢癌组织中的表达及其临意义,第三军医大 学学报,2006,10,28(20),2054-2056.
246.苍亚芹,马致南。乙酰肝素酶在卵巢癌中表达的临床意义。黑龙江医学2007年05期。
247.Folkman J.Control of angiogenesis by heparin and other sulfated polysaccharides Advance in Experimental.[J]Medicine and Biology.1992;313:355-364.
248.Mesiano S,Jaffe RB,Jaffe RB,Role of vascular endothelial growth factor in ovarian cancer:inhibition of ascites formation by immunoneutralization[J]American Journal Of Pathology.1998;153:1249.
249.E S Bamberger and C W PerrettAngiogenesis in epithelian ovarian cancer.[J]Molecular Pathology;2002;55:348-359.,
250.Masatsugu Ueda,Yao-Ching Hung,Yoshito Terai,et al.Vascular Endothelial Growth Factor-C Expression and Invasive Phenotype in Ovarian Carcinomas[J]Clinical Cancer Research Vol.11,3225-3232,May 1,2005.
251.杨鹰,韩静,阎萍等,乙酰肝素酶在卵巢癌中的表达及其与肿瘤血管生成的关系。重庆医学。2006年24期。
252.Mohler JL,Partin AW,Isaacs JT,Coffey DS(1988)Metastatic potential prediction by a visual grading system of cell motility:prospective validation in the Dunning R-3327 prostatic adenocarcinoma model.Cancer Res 48:4312-4317.
253.A Ayhan,M Gultekin,C Taskiran,et al.Ascites and epithelial ovarian cancers:a reappraisal with respect to different aspects.[J]Int J Gynecol Cancer,January 1,2007;17(1):68-75.
254.Toh Y,Pencil SD,Nicolson GL.et al.A novel candidate metastasis-associated gene,mtal,differentially expressed in highly metastatic mammary adenocarcinoma cell lines.cDNA cloning,expression,and protein analyses.The Journal of biological chemistry.1994;269(37):22958-22963.
255.Wiemik PH,Schwartz EL,Strauman JJ.et al.Phase I clinical and pharmacokinetic study oftaxol[J].Cancer Res,1987,47(12):2486-2493.
256.Hollingsworth HC,Kohn EC,Steinberg SM,et al.Tumor angiogenesis in advanced stage ovarian carcinomas.Am J Pathol,1995,147(1):33- 41
257.李劲涛,杨 军,张秀丽等。RNAi最新研究概况。[J]细胞与分子免疫学杂志2007, 23(11):1077-1079.
258.Bustin SA.Absolute quantification of mRNA using realtime reverse transcription polymerase chain reaction assays[J].Mol Endocrinol,2000,25:169.
259.汪洋,宫琳琳,邵淑娟。实时荧光定量PCR在肿瘤研究中的应用。[J]肿瘤2004,24(2):196-198.
260.Orit Goldshrnidt,Eyal Zcharia,Miriam Cohen,et al.Heparanase mediates cell adhesion independent of its enzymatic activity.The FASEB Journal.2003;17:1015-1025.
261.Evgeny Edovitsky,Michael Elkin,Eyal Zcharia,et al.Heparanase Gene Silencing,Tumor Invasiveness,Angiogenesis,and Metastasis.JNCI Journal of the National Cancer Institute 2004 96(16):1219-1230.
262.Anna Zetser,Yulia Bashenko,Hua-Quan Miao,et al.Heparanase Affects Adhesive and Tumorigenic Potential of Human Glioma Cells[J]Cancer Research 63,7733-7741,November 15,2003.
263.L.Kjellen andU.Lindahl.Proteoglycans:Structures and interactions.Annu.Rev.Biochem.1990;60:443-475.
264.M.Bernfield,M.Gotte,P.W.Park,et al.Functions of cell surface heparan sulfate proteoglycans.Annu.Rev.Biochem.1999;68:729-777.
2.Fidler IJ:The organ microenvironment andcancer metastasis.Differentiation2002;70:498-505.
3.Fidler IJ:Critical determinants of metastases.Semin Cancer Bio12002;12:89 - 96.
4.Kuwata T,Kitagawa M,Takemura T,etal.Proliferative activity and P53 over-expression of ovarian epithelia tumors.Gen Diagn Pathor,1995:14(2):131-139.
5.Strauli P,Haemmerli G.The role of cancer cell motility in invasion.Cancer Metastasis Rev.1984;3(2):127-141.
6.Volk T,Geiger B,Raz A.Motility and adhesive properties of high- and low-metastatic mufine neoplastic cells.Cancer Res.1984;44(2):811-824.
7.Antoni Castells,Anil K.Rustgi.Tumor Invasion and Metastasis.
8.Li AJ,Madden AC,Cass I,etal.The prognostic significance ofthrombocytosis in epithelial ovarian carcinoma.Gynecol Oncol.2004;92(1):211-214.
9.Nicolson GL.Metastatic tumor cell attachment and invasion assay utilizing vascular endothelial cell monolayers.J Histochem Cytochem.1982;30(3)::214-220.
10.Paget S.The distribution of secondary growths in cancer of the breast[J].Lancet.1889;1:571-573.
11.Rose PG,Piver MS,Tsukada Y,Latus.Metastatic patterns in histologic variants of ovarian cancer.An autopsy study.Cancer 1989;64(7):1508-13.
12.Wu PC,Lang JH,Huang TL,et,al.lymph node metastasis and retroperitoneal lmmphadenectpmy in ovarian cancer.Clin Obstet Gynecol,1989,83(8):1555-1560.
13.Onda T,Yoshikawa H,Yasugi T,etal.Patients with ovarian carcinoma upstaged to stageⅢ after systematic lymphadenctomy have similar survival to Stage Ⅰ/Ⅱ patients and superior survival to other Stage Ⅲ patients.Cancer,1998;83(8):1555-1560.
14.Pereira A,Magrina JF,Rey V,et al.Pelvic and aortic lymph node metastasis in epithelial ovarian cancer.Gynecol Oncol.2007 Jun;105(3):604-8.
15.Canino F.Significance of lymph node sampling in epithelia carcinoma of the ovary.GynecoOnco,1997;65(3):467.
16.吴小华,张志毅,唐美琴.卵巢恶性肿瘤腹膜后淋巴结转移率及危险因素的临床研究[J]。中华妇产科杂志,1996;31:543-547.
17.沈铿,郎景和,连利娟,等.Ⅰ期卵巢上皮性癌全面分期探查术的临床意义[J]。中华妇产科杂志,1996,31(7):390.
18.蒋庆春,来婷。卵巢癌腹膜后淋巴结清除的临床意义[J].中华医学杂志,1998,78(1):77-78.
19.王文福,孙蕊,马玲.晚期卵巢上皮癌腹膜后淋巴结转移清除的合理选择[J].中华妇产科杂志,1999,34(2):108-109.
20.周晖。妇科常见恶性肿瘤的腹膜后淋巴结转移[J].实用癌症杂志,1999,14(2):156-158。
21.黄光琦,贺国丽,宋毅,等.几种肿瘤转移基因变化与卵巢转移的相关性。华西医科大学学报,2002,33(1):28-31.
22.Toh Y,Kunimaks S,Endo K,et al.Molecular analysis of a candidate metastesis-associated,MTA1:posible inferation with histone decay case.Exp Clin Cancer Res,2000,19(1):105.
23.NawaA,Nishimori K,Lin P,et al.Tumer metastasis-associated human MTA1 gene:its deduced protein sequence,localization and associated with breast cancer cell proliferation using antisense phosphorothioate oligonucieotidesl.J Cell Biochem,2000,79(2):202.
24.Tchernitsa OI,Sers C,Zuber J,et al.Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells.Oncogene.2004:23(26):4536-4555.
25.Cautrecasas M,Erill N,Musulen E,et al.K-ras mutations ovarian epithelial tumers:a molecular analysis and clinicopathologic study of 144 patients.Cancer,1998,82(6):1088-1095.
26.Suzuki E,Ota T,Tsukuda K,et al.nm232H1 reduces in vitro cdllmigration and the liver metastatic potential of colon cancer cellsby regulating mypsin lightchain hosp horylation.Int[J].Can2cer,2004,10(8):207.
27.Steeg PS,Bevilacqua G,KooperL,et al.Evidence for a novel gene associated with low tumor metastatic potential[J].J Nail Cancer Imt,1988,80:200.
28.Sadek CM,J imenez A,Damdimopoulos AE,et al.Characterization of human thioredoxin -like 2.A novelmicrotu - bule.binding thioredox2 in expressed p redominantly in thecilia of lung airway epithelium and spermatid manchette and axoneme[J].J Biol Chem,2003,(15):278.
29.温凯辉,温砾,辛晓燕,卢小娟,李青.p53过表达、nm23低表达与卵巢浸润、转移关系的探讨。J Diag Pathol,2005(10):450-452。
30.Kapitanovic S,Spavent iR,Vujsic S,etal.Nm23-H1 gene expression in ovarian tumor potential tumor marker.Anticancer Res,1995,15(2):587
31.Dong J T,Lamb PW,Rinker2Schaeffer CW,et al.KAI1,a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2.Science,1995,268:884-886.
32.Christopher D,Xiao Yu D,J ulie F,et allLoss of expression and altered localization of KAI1 and CD9 protein are associated with epithelialovrian cancer progressionlGynecol Oncol,2002,86:6978
33.宋晖,辛晓燕,肖锋,等1肿瘤转移抑制基因KAI1对卵巢癌细胞增殖及侵袭能力的影响 现代妇产科进展,2003,12(5):3483501.
34.Kareen Blechschrnidt,Elisabeth Kremmer,Regina Hollweck,et al.The E-cadherin Repressor Snail Plays a Role in Tumor Progression of Endometrioid Adenocarcinomas.[J]Diagn Mol Pathol.2007 Dec;16(4):222-228.
35.Bramanandam,Manavathi and Rakesh Kumar.Metastasis Tumor Antigens,an Emerging Family of Multifaceted Master Coregulators[J].Biol.Chem.,Vol.282,Issue 3,1529-1533,January 19,2007
36.Nagfuchi A,Takei M1Cell binding function of E2cad is regulated by the cytoplastic domainlEmbo J,1998,7:367936841.
37.Davidson B,Gotlieb WH,Ber-Baruch G,et al.E-Cadherin complex protein Expression and survival in ovarian carcinoma.Gynecol Oncol.2000,78(3):362-371
38.李晓鸣,朱任之.乳腺髓样癌与粘附因子[J]。中国医学文摘.肿瘤学,2002,16(1):79-81。
39.J Behrens,L Vakaet,R Friis,et al.Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/betaocatenin complex in cells transformed with a temperature-sensitive v-SRC gene.The Journal of Cell Biology,1993;120:757-766.
40.Darai E,Leblane M,Walker CF,et al.Expression of adherins and CD44 isoforms in ovarian endometrial lysts.Human Reproduction.1998,13(5):1346.
41.Loftus J C,Liddington R C.Cell adhesion in vascular biology New insight into integrin-lingand interactinn.J Clin Invest,1997,99(10):2302-2306.
42.F Mitjans,D Sander,J Adan,A Sutt,et al Role of the α_vβ_3 Integrin in Human Melanoma.Cell Invasion.National Academy of Sciences,Vol 89,1557-1561.
43.N Ahmend,F Pansino,Riley Clyde,et al;Overexpression of avβ6 integrin in serious
44.Abe Y,et al.Adefect in cell-to-cell,adhesion viaintegrin- fibronectin interactions in a highly metastatic tumor cellline.[J]Japanese Journal of Cancer Research.1997;88(1):64-71.
45.Sood AK,Coffin JE,Schneider GB,et al;Biological sig-nificance of focal adhesion kinase in ovarian cancer[J][M];Am J Pathol;2004.
46.Sellar GC,Watt KP,Rabiasz GJ,Stronach EA,Li L,Miller EP,et al OPCML at 11q25is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer.Nat Genet 2003:34(3):337-343.
47.姚德生,李力,Kenneth Garson,Barbara C Vanderhyden.OPCML对卵巢癌细胞抑制的体内外实验研究
48.卢建,纪晓峰,江道振,张金山.E-选择素及其配体在人卵巢癌细胞与血管内皮细胞粘附中的作用.中国病理生理杂志,1999,15(11)
49.Schadendorf D,Diehl S,Zuberbier T,et al;Quantitative detection of soluble adhesion in sera of melanoma patients correlates with clinical stage.Dematology 1996,192:89-93.
50.钱思源,王黎娜,刘惠喜.P-选择素在卵巢癌中表达的意义.武警医学,2001,12(9):520.
51.Subramaniam V,Vincent IR,Gardner H,et al.CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation.Exp Mol Pathol.2007 Oct;83(2):207-15.
52.Schroder W,Biesterfeld S Biesterfeld S et al.Expression of CD44(V5 10)splicing variants in primary ovrian cancer and lymph node metastases[J].Anticancer Res,1999,19(5B):3901-3906.
53.Saegusa M,Machida D,Hashimura M,Okayasu I.CD44 expression in benign premalignant,and malignant ovarian neoplasms:relation to tumour development and progression.J Pathol.1999 Nov;189(3):326-37.
54.姚忠强,李力.恶性卵巢肿瘤中CD44V6基因蛋白表达的检测及其意义.肿瘤防治杂志。2000,27(1):4-6.
55.Stickeler E,Vogl FD,Denkinger T,et aloCD44 splice variants and pelvic lymphnode metastasis in ovarian cancer patients[J].Int J Mol Med,2000,6(5):595-601.
56.王忠民,王波,汪洁平,叶萍.血清sCD44v6PCA125检测在卵巢癌患者中的临床应用。中国妇产科临床杂志2003 Nov;14(16)431-435.
57.Folkman J.What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
58.Fidler I J,Ellis L M.The implications of angiogenesis for the biology and therapy of cancer metastasis.Cell,1994,79(2):185-188.
59.Ferrara N.Henzel WJ.Pituitary follicalar cell secrete a novel heparinbonding growth factor specifictor vascular endothelial cell[J].Bio chem Biophys Res lommun,1989,161(2)851.
60.Abu Jawdeh GM,Niloff J,Niloff.Strong expression of vascular permeability factor (vascular endothelial growth factor)and its recptors in ovarian borderline and malignant neoplass.[J]Laboratory Investigation1996,74(6):1105-1115.
61.Michael J.Callahan,John P.Vascular endothelial growth factor(VEGF)and cyclooxygenase 2(COX 2)immunostaining in ovarian cancer Proc Amer Assoc Cancer Res,Volume 452004.
62.Harlozinska A,Kulpa J,Kulpa:Vascular endothelial growth factor(VEGF)concentration in sera and tumor effusions from patients with ovarian carcinoma.Anticancer Research,2004,24(2):1149-1157
63.罗仪,陈双郧,刘永珍等,血管内皮生长因子诊断和监测卵巢恶性肿瘤的临床研究。中国实用妇科与产科杂志,2001年06期
64.DP Barton,A Cai,K Wendt,et al.Angiogenic protein expression in advance epithelial ovarian cancer.Clinical Cancer Research,,Vol 3,Issue 9 1579-1586.
65.Fujimoto J,Ichigo S,etc.Expression of basic fibroblast growth factor and its mRNA in advanced ovarian cancer.Eur J Gynecol Oncol.1997,349-35.
66.王旭平,阎莉荣,毕胜利等,卵巢癌患者围手术期血清bFGF、ColⅣ、HA的变化及 临床意义实用肿瘤学杂志。2007;21(4):316-318.
67.Sakata K,Shigemasa K,Nagai N,et al.Expression of matrix metalloproteinases(MMP2,MMP-9,MT1-MMP)and their inhibitors(TIMP- 1,TIMP- 2)in common epithelial tumors of the ovary.Int J Oncol,2000,17:673-6811.
68.胡晓霞,李力,黎丹戎等,基质金属蛋白酶-2及基质金属蛋白酶组织抑制剂-2在卵巢恶性肿瘤中的表达及其意义。广西医科大学学报,2004,21(5):625-628.
69.Isogai C,Laug W E,Shimada H,et al.Plasminogen activator inhibitor-1 promotes angiogensis by stimulating endothelial cell migration toward fibronectin.Cancer Res,2001,61(14):5587-5594.
70.Hapke S,Kessler H,Arroyo de Prada N,et al.Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.J Biol Chem.2001:276(28):26340-26348.
71.Schmalfeldt B,et al.Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator,its receptor,and inhibitors types 1 and 2.Cancer Res,1995,55(18):3958-3963.
72.梁兰 纤溶酶原激活因子及其抑制因子mRNA表达与卵巢临床病理联系。2004,103-105.
73.SCORILAS A,FOTIOU S,TSIAMBAS E,et al.Determination of cathepsin B expression may offer additional prognostic information for ovarian cancer patients.Biol Chem,2002,383(728):1297-1303.
74.王中显,刘少扬,江大琼.组织蛋白酶B在卵巢癌中的表达及意义.肿瘤,2006 26(6):559-562.
75.Nishida Y,Kohno K,Kawamata T,etc.Increased cathepsin L levels in serum in some patients with ovarian cancer:comparison with CA125 and CA72-4.Gynecol Oncol.1995Mar;56(3):357-361.
76.秦捷。纤溶酶原激活因子及其抑制因子与卵巢癌侵袭转移关系的研究。2007;6:144-148.
77.连利娟.卵巢上皮性癌与交界性瘤的临床[A].见:连利娟 主编.林巧稚妇科肿瘤学[M].第四版.北京:人民卫生出版社.2006,553-554.
78.郎景和,沈铿,向阳.临床妇科肿瘤学[M].北京:人民卫生出版社,2003.290-296.
79.Ali Ayhan,Murat Gultekin,Cagatay Taskiran,et al.Routine Appendectomy in Epithelial Ovarian Carcinoma:Is It Necessary?[J]Obstetrics & Gynecology 2005;105:719-724
80.Parazzini F,Valsecchi G,Bolis G,etal.Pelvic and paraotic lymph nodal status in advanced ovarian cancer and survival.Gynecol Oncol,1999;74(1):7-11.
81.Canino F o Significance of lymph node sampling in epithelia carcinoma of the ovary.Gyneco Onco,1997;65(3):467.
82.Sidmey SC,Louise L.Incidence of paraaortic and pelvic lymph node metastasis in epithelial carcinoma of the ovary.Gynecol Oncol 1983;16:95
83.郎景和。Ⅰ期卵巢癌的淋巴结转移所见:郎景和主编。卵巢肿瘤的基础及临床研究.北京:北京医科大学 中国协和医科大学联合出版社,1996.300-320
84.齐振红,姜玉新,程玉芳,王蕾;超声在早期卵巢癌诊断中的价值.[J]中华超声影像学杂志;2004;5:45-47.
85.林黎娟;卵巢恶性肿瘤的CT表现.[J]中国辐射卫生.2008;17(1):90.
86.罗淑贞,郭友,陈空等;对多排螺旋CT诊断卵巢癌腹膜转移的临床评价。实用医学杂志。2004;20(12):1381-1382.
87.Meyers MA.Distribution of intra-abdominal malignant seeding:dependency on dynamics of flow of ascitic fluid.Am J Roentgenol Readium Ther Nucl Med,1973,119(1):198 -206
87.Coakley FV,Choi PH,Gougoutas CA,et al.Peritoneal metastases:detection with spiral CT in patients with ovarian cancer.Radiology.2002 May;223(2):495-9.
88.吴珊珊,万云,刘波等,卵巢肿瘤的MRI诊断与鉴别诊断.现代临床医学生物工程学杂志.2006;12(2):119-122.
89.朱强等,CT磁共振成像在原发性卵巢癌分期中的应用,中华肿瘤杂志,1999,21(4):296-299.
90.Tempany CM,,Zou KH,,Silverman SG,,et al.Staging of advanced ovarian cancer:comparison of imaging modalities--report from the Radiological Diagnostic Oncology Group.Radiology.2000;215(3):761-767.
91.Kurokawa T,Kawahara K,Kawahara K.Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range.[J]Annals of Nuclear Medicine.2002;16:491-493.
92.Torizuka T,Kanno T,Kanno T.Ovarian cancer recurrence:role of whole-body positron emission tomography using2[fluorine-18]-fluoro-2-deoxy-D-glucose.Eur J Nucl Med Mol Imaging,2002;29(6):797-803.
93.Barranger E,Petegnief Y,Petegnief Y.Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intraoperative probe guidance in a woman with recurrent ovarian cancer.[J]Gynecol Oncol 2005;96:241-244.
94.Rieber A,Stohr I,Stohr I,et al.Preoperative diagnosis of ovarian tumor with MR imaging:comparison with transvaginal sonography,positron emission tomography,and histologic findings.[J].A-J-R 2001;177:123-129.
95.Harpreet K.Pannu,Robert E.Bristow,Christian Cohade,et al.PET-CT in Recurrent Ovarian Cancer:Initial Observations.[J].Radiographics.2004;24:209-223.
96.Smith GT,McDonald T,McDonald T,et al.Cost analysis of FDG PET for managing patients with ovarian cancer.[J].Clin Positron Imaging 1999;2(2):63-70.
97.赵军,管一晖,左传涛等,18F-FDG PET/CT在探测卵巢癌术后复发和转移中的价值。中国肿瘤。2007;3。
98.李春海.肿瘤标志学基础与临床.北京,军事医学科学出版社.2007.10
99.Yang G,Thompson-Lanza,et al.Inhibition of breast and ovarian tumor growth through multiple signaling pathways by retrovirus-mediated siRNA silencing against Her-2/neu gene expression.[J]Journal of Biological Chemistry.2003;18:15-21.
100.Gao D,Lu Y,Lu Y,et al..Significance of HER-2/neu expression in ovarian epithelial tumours.Zhonghua,Bing Li Xue Za Zhi.2002 Jun;31(3):268-70.
101.Alessandra V,Vincenzo C,et al.Suppressive role of metastasis related nm23-H1 gene in human ovarian carcinomas:Association of high messenger RNA expression with lack of lymaph node metastasis.[J]Cancer Research.1995;55:2642.
102.Masaki Mandai,Ikuo Konishi,Masafumi Koshiyama.et al.Expression of Metastasis-related nm23-H1 and nm23-H2 Genes in Ovarian Carcinomas:Correlation with Clinicopathology,EGFR,c-erbB-2,and c-erbB-3 Genes,and Sex Steroid Receptor Expression.Cancer Research.1994,April 1,54:1825-1830.
103.高庆蕾,马丁,孟力等,nm23基因表达与卵巢癌转移的相关性。癌症,2004, 23(6):650-654。
104.温凯辉,温砾,辛晓燕等,p53过表达、nm23低表达与卵巢癌浸润、转移关系的探讨。诊断病理学杂志2005,12:6450-452.
105.Katsuo Morita,Yuko Ono,Hirokazu Fukui.Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors[J].Pathology International.2000 March 3(50):219-223.
106.邬东平,陈惠祯,龚玲玲。卵巢癌p53蛋白表达与细胞增殖状态及预后的关系肿瘤防治研究2003,30(4):294-295。
107.Yin BW,Lloyd KO.Molecular cloning of the CA125 ovarian cancer antigen:identification as a new mucin,MUC16.[J].Biol Chem.2001,Jul,20;276(29):27371-5.
108.Kumar P,Rehani MM,Kumar L,et al.Tumor marker CA-125 as an evaluator and response indicator in ovarian cancer:its quantitative correlation with tumor volume.[J]Med Sci Monit.2005 Feb;11(2):CR84-9.
109.Rustin GJ,Nelstrop AE,Tuxen MK,et al.:Defining progression of ovarian carcinoma during follow-up according to CA 125:a North Thames Ovary Group study.Annals of Oncology 1996,7(4):361-364.
110.Dong L,Cui H,Li XP,et al.Clinical value of serum CA19-9,CA125 and CP2 in mucinous ovarian tumor:a retrospective study of 273 patients.Zhonghua Fu Chan Ke Za Zhi.2008 Jan;43(1):5-8.
111.Kataoka A,Yakushiji M.A study of localizations and serum data;four tumor markers (CA125,CA19-9,CEA and TPA)in ovarian cancers.Nippon Gan Chiryo Gakkai Shi.1990Jan 20;25(1):47-54.
112.Fukatsu T,Nakashima N,Takeuchi J.Diagnosis of ovarian tumor by measuring tumor markers.Rinsho Byori.1992 Feb;40(2):133-8.
113.Dong Y,Kaushal A,Bui L,et al.Human kallikrein 4(KLK4)is highly expressed in serous ovarian carcinomas.Clin Cancer Res.2001 Aug;7(8):2363-71.
114.Ying Dong,Aneel Kaushal,Loan Bui,et al.Human Kallikrein 4(KLK4)Is Highly Expressed in Serous Ovarian Carcinomas.Clinical Cancer Research Vol.2001 August 7:2363-2371,
115.Obiezu CV,Scorilas A,Katsaros D.et al.Higher human kallikrein gene 4(KLK4)expression indicates poor prognosis of ovarian cancer patients.Clin Cancer Reso 2001 Aug;7(8):2380-6.
116.Ying Dong,Aneel Kaushal,Loan Bui,et al.Human Kallikrein 4(KLK4)Is Highly Expressed in Serous Ovarian Carcinomas.Clinical Cancer Research Vol.2001 August 7:2363-2371.
117.Beaufort N,Debela M,Creutzburg S,et al.Interplay of human tissue kallikrein 4(hK4)with the plasminogen activation system:hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor(uPAR).Biol Chem.2006 Feb;387(2):217-22.
118.Prezas P,Arlt MJ,Viktorov P,et al.Overexpression of the human tissue kallikrein genes KLK4,5,6 and 7 increases the malignant phenotype of ovarian cancer ceils.Biol Chem.2006Jun;387(6):807-11.
119.Hoffman BR,Scorilas A,Scorilas A,et al.Immunofluorometric quantitation and histochemical localization of kallikrein 6 protein in ovarian cancer tissue:a new independent unfavourable prognostic biomarker.Br J Cancer 2002;87(7):763-771.
120.曹泽毅 主编.妇科肿瘤学(下篇)[M].第一版.北京:北京出版社,1998,830-838.
121.Brughardt E,Girardi F,Lahousen M,etc.Patterns of pelvic and paraaotic lymph node involvement in ovarian cancer.Gynecol Oncol,1997;40(2):103-106.
122.沈铿,郎景和。妇科肿瘤临床决策。第一版.北京:人民卫生出版社,2007.10,10-11。
123.Bristow RE,Armstrong DK,Armstrong DK,et al.Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era:a meta-analysis.Journal of Clinical Oncology.2002;20(5):1248-1259.
124.李孟达,李玉洁,黄永文,等.影响上皮性卵巢癌远期疗效的因素分析。癌症,2004,23(11):1306-1310.
125.Onda T,yashikawa H,Yasugi T,et al.Assessment of metastases to aortic and pelvic lymph nodes in eptithelial ovarian cancer.[J]Cancer.1996;78:903-908.
126.缪智辉,殷平等,卵巢癌患者大网膜切除的临床病理分析。2001,23(6):650-654。
127.E S Bamberger and C W Perrett.Angiogenesis in epithelian ovarian cancer.[J]Mol.Pathol.Dec 2002;55:348-359.
128.YF Shi and YP Cheng.Zhonghua Fu Chan Ke Za Zhi,March 1,1990;25(2):70-2,
129.EW Munnell.The changing prognosis and treatment in cancer of the ovary.A report of 235 patients with primary ovarian carcinoma 1952-1961.[J]Am J Obstet Gynecol,Mar 1968;100(6):790-805.
131.Parker R T.Cancer of the ovary survival study based upon operation therapy chemotherapy and radiotherapy.Am J Obstet Gynecol,1970,188;878.
132.姚德生,李力。卵巢上皮性癌手术治疗现状。[J]浙江肿瘤。2000,6(4):241-245。
133.Wu PC,Huang RL,Huang RL,et al.Lymph node metastasis and retropcritoneal lymphadennectomy in ovarian cancer.[J]Baillier's Clinical Obstetrics and Gynaecologyo 1989;3:143.
134.P Morice,F Joulie,S Camatte,et al.Lymph node involvement in epithelial ovarian cancer:analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications.J Am Coll Surg,August 1,2003;197(2):198-205.
135.吴小华,张志毅,唐美英,等.卵巢恶性肿瘤的腹膜后淋巴转移率及危险因素的临床研究[J]中华妇产科杂志,1996,31(9):543-547.
136.JK Chan,R Urban,JM Hu,et al.The potential therapeutic role of lymph node resection in epithelial ovarian cancer:a study of 13918 patients.Br J Cancer,June 18,2007;96(12):1817-22.
137.Di Re F.Value of lymph node assessment in ovarian cancer:Status of the art at the end of the second millennium.[J]International Journal of Gynecological Cancer.2000;10(6):435-442.
138.M Suzuki,M Ohwada,T Yamada,et al.Lymph node metastasis in stage I epithelial ovarian cancer.[J]Gynecol Oncol,November l,2000;79(2):305-8.
139.Faught W,Le T,Fung Kee Fung M,et al.Early ovarian cancer:what is the staging impact of retroperitoneal node sampling?[J]Obstet Gynaecol Can.2003 Jan;25(1):18-21.
140.Stratton JF,Tidy JA,Paterson MEL.The surgical management of ovarian cancer.Cancer Treat Rev,2001,27(2):111-118.
141.Di Re F,Raspagliesi F,et al.Pelvic and paraaortic lymphadenectomy in cancer of the ovary.[J]Clinical Obstetrics and Gynaecology.1989;3(1):131-142.
142.D Guthrie,ML Davy,and PR Philips A study of 656 patients with "early" ovarian cancer.[J]Gynecol Oncol,Mar 1984;17(3):363-9.
143.Yokoyama Y,Sato S,Sato S,et al.Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer.[J]European Journal of gynaecological oncology.1999;20,5-6:361-366.
144.Poncheville L,Lefrancq T,Lefrancq T,et al.Does paraaortic lymphadenectomy have a benefit in the treatment of ovarian cancer that is apparently confined to the ovaries?[J]Eur J Cancer.2001;37:210-215.
145.余冬青,李力。卵巢上皮性癌腹膜后淋巴结清扫的临床价值[A];中华医学会第九次全国妇科肿瘤学术会议论文汇编[C];2006年。
146.EISENKOP S M,SPIRTOS N M.The clinical si fi eanee of occult maeroscopieally positive retroperitoneal nodes in patients with epithelial ovarian eancer[J].Gyneeol Oncol,2001,82:143-149
147.P_Benedetti Panici,G Perniola,R Angioli,et al.Bulky lymph node resection in patients with recurrent epithelial ovarian cancer:impact of surgery.Int J Gynecol Cancer,November 1,2007;17(6):1245-51.
148._赵晶,刘新民。卵巢恶性肿瘤手术同时切除阑尾53例分析(J)现代妇产科进展,1996,5(1):38-40。
149.张亦文,刘新民,孙玉蓉.妇科手术同时切除阑尾的探讨[J].中国实用妇科与产科杂志,2001,17(3):165。
150.李力.卵巢癌阑尾切除临床分析[J].临床外科杂志,2001,1,9.
151.Westermann G,Mann WJ,Chumas J,etc.Routine appendectomy in extensive gynecologic operation.Surg Gynecol Obsted,1986,162:307.
152.Ayhan A,A1 RA,Baykal C,etc.The influence of splenic metastases on survival in FIGO stage ⅢC epithelial ovarian cancer[J].Int J Gynecol Cancer,2004,14(1):51- 56.
153.Pedro T.Ramireza,Brian M.Slomovitza,Lacey McOuinnb,et al.Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer.[J]Gynecol Oncol.2006 Dec;103(3):888-90.
154.Malfetano JH.The appendix and its metastatic potential in epithelial ovarian cancer.Obstet Gynecol,1987,69:396.
155.Fontanclli R,Paladini D,Raspagliesi F,etc.The role of appendectory in surgical procedures for ovarian cancer.Gynecol Oncol,1992,46:42-43.
156.Natalina Manci,Filippo Bellati,Ludovico Muzii,et al.Splenectomy During Secondary Cytoreduction for Ovarian Cancer Disease Recurrence:Surgical and Survival Data.[J]Annals of Surgical Oncology 13:1717-1723(2006).
157.T Bilgin,K Ozerkan,and H Ozan.Splenectomy in cytoreductive surgery for advanced ovarian cancer.[J]Arch Gynecol Obstet,April 1,2005;271(4):329-31.
158.LM Chen,RS Leuchter,LD Lagasse,and BY Karlan.Splenectomy and surgical cytoreduction for ovarian cancer.[J]Gynecol Oncol,June 1,2000;77(3):362-8.
159.SM Eisenkop,NM Spirtos,and WC Lin.Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer.[J]Gynecol Oncol,February 1,2006;100(2):344-8.
160.PM Magtibay,PB Adams,MB Silverman,et al.Splenectomy as part of cytoreductive surgery in ovarian cancer.[J]Gynecol Oncol,August 1,2006;102(2):369-74.
161.A Ayhan,RA Al,C Baykal,et al.The influence of splenic metastases on survival in FIGO stage ⅢC epithelial ovarian cancer.[J]Int J Gynecol Cancer,January 1,2004;14(1):51-6.
162.W Cliby,S Dowdy,SS Feitoza,et al.Diaphragm resection for ovarian cancer:technique and short-term complications.[J]Gynecol Oncol,September 1,2004;94(3):655-60.
163.DF Silver.Full-thickness diaphragmatic resection with simple and secure closure to accomplish complete cytoreductive surgery for patients with ovarian cancer.[J]Gynecol Oncol,November 1,2004;95(2):384-7.
164.GD Aletti,SC Dowdy,KC Podratz,et al.Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer.[J]Gynecol Oncol,February 1,2006;100(2):283-7.
165.杨来春,段涛,朱关珍.铁林迪妇科手术学[M].济南:山东科学技术出版社,2003.1453-1463.
166.张师前,智绪亭,李家福。晚期卵巢癌理想肿瘤细胞减灭术可行性研究[J]。中国现代手术学杂志,2004,8(6):345-347。
167.Cai HB,Zhou YF,Chen HZ.et al.The role of bowel surgery with cytoreduction for epithelial ovarian cancer.[J]Clin Oncol(R Coll Radiol).2007 Dec;19(10)757-62.
168.S Abdul et al.Can we identify the patients likely to undergo bowel resection at the time of operation for ovarian cancer?[J]Obstetrics and Gynaecology;May 2006,26(4),357-62.
169.Ritu Salania,Marianna L.Zahurakb,et al.Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer:A case-control study.[J]Gynecologic Oncology.2007;107(3):495-499.
170.Tien Le,FRCSC,Ghadeer Alshaikh,et al.Prognostic Significance of Postoperative Morbidities in Patients With Advanced Epithelial Ovarian Cancer Treated With Neoadjuvant Chemotherapy and Delayed Primary Surgical Debulking.[J]Annals of Surgical Oncology 2006;13:1711-1716.
171.Steed H,Oza AM,Murphy J,et al.A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer.[J]International Journal of Gynecological Cancer.2006 February;16(1):47-53.
172.王世阆等,卵巢疾病,人民卫生出版社[M],2004.1:237.
173.Ozols RF,Btmdy BN,GreerBE,et al.Phase Ⅲ trial of calboplatin and paclitaxel compared with cisplatin and paclitaxd in patients with optimally resected stage Ⅲ ovarian Cancer:a Gynecology Oncoloy Group study[J].Clin Oncol,2003,21(17):3194-3200.
174.S.W.Hansen.Gemcitabine in the treatment of ovarian cancer.International.[J]Journal of Gynecological CancerVolume.2001 July;11(1):39-41.
175.Muggia F.Phase Ⅲ data on Caelyx in ovarian cancer.[J]European Journal of Cancer.2001;37:15-18.
176.McGuire WP,Hoskins WJ,Brady MF,et al.Cyclophosphamide and cisplatin versus paclitaxel and cisplatin:a phase Ⅲ randomized trial in patients with suboptimal stage Ⅲ/Ⅳovarian cancer(from the Gynecologic Oncology Group).Semin Oncol.1996 Oct;23(5 Suppl 12):40-7.
177.J.TateThigpen.Multi-Center 5-Arm Randomized Trial of Initial Chemotherapy for Advanced Ovarian Cancer
178.Muggia FM,Brady MF,Brady MF,et al.Phase Ⅲ randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage Ⅲ or Ⅳ ovarian cancer:a gynecologic oncology group study.[J]Journal of Clinical Oncology.2000;18(1):106-115.
179.李君凤.TPC化疗方案治疗晚期卵巢癌的疗效观察.临床和实验医学杂志。2007;6(2):56-58。
180.刘俊宝,冷维春,张爱臣等,TP及CAP化疗方案治疗晚期卵巢癌的比较。[J]中华现代妇产科学杂志.2005;2(2):110-112。
181.Armstrong DK,Bundy B,Wenzel L,et al.Intraperitoneal cisplatin and paclitaxel in ovarian cancer.[J]N Engl J Med 2006;354:34-43.
182.Piccart MJ,Gore M,Ten Bokkel Huinink W,et al.Docetaxel:An active new drug for treatment of advanced epithelial ovarian cancer.[J]Natl Gancer Inst,1995,87:676-681.
183.du Bois A,Luck HJ,Meier W,etc.A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.J Natl Cancer Inst.2003Sep3;95(17):1320-9.
184.Vasey PA,Jayson GC,Gordon A,etc.Phase Ⅲ randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.J Natl Cancer Inst.2004 Nov 17;96(22):1682-91.
185.Mori T,Hosokawa K,Kinoshita Y.etc.A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer._Int J Clin Oncol.2007 Jun;12(3):205-11.Epub 2007 Jun 27.
186.Andreas du Bois,Hans-Joachim Luck,Weaner Meier,et al.A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer.JNCI Journal of the National Cancer Institute 2003 95(17):1320-1329.
187.Pfisterer J,Weber B,Reuss A,etc.Randomized phase Ⅲ trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer:a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.J Natl Cancer Inst.2006 Aug 2;98(15):1024-6.
188.Mauricio Cuello,Seth A.Ettenberg,Amy So Clark,et al.Down-Regulation of the erbB-2Receptor by Trastuzumab(Herceptin)Enhances Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated Apoptosis in Breast and Ovarian Cancer Cell Lines that Overexpress erbB-2.[J]Cancer Research 61,4892-4900,June 15,2001.
189.Michael A.Bookman,Kathleen M.et al.Evaluation of Monoclonal Humanized Anti-HER2 Antibody,Trastuzumab,in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2:A Phase Ⅱ Trial of the Gynecologic Oncology Group.[J]Journal of Clinical Oncology,Vol 21,Issue 2(January),2003:283-290.
190.S.Makhija,D.Glenn,F.Ueland,M.et al.Results from a phase Ⅱ randomized,placebo-controlled,double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian,fallopian tube,or primary peritoneal cancer.Journal of Clinical Oncology,2007 ASCO Annual Meeting Proceedings Part Ⅰ.Vol 25,No.18S(June 20 Supplement),2007:55
191.Berek JS,Schultes BC,Nicodemus CF.Biologic and immunologic therapies for ovarian cancer.[J]Clin Oncol.:2003 May 15;21(10 Suppl):168s-174s
192.Thomas G Ehlen,Alan N Gordon,Howard J Fingert,et al.Adjuvant treatment with monoclonal antibody,OvaRex MAb-B43.13(OV)targeting CA125,induces robust immune responses associated with prolonged time to relapse(TTR)in a randomized,placebo-controlled study in patients(pts)with advanced epithelial ovarian cancer(EOC).2002 ASCO Annual Meeting.
193.Deborah K.Armstrong,John A.Blessing,Katherine Y.Look,et al.A randomized phase Ⅱ evaluation of bryostatin-1(NSC #339555)in recurrent or persistent platinum-sensitive ovarian cancer:A Gynecologic Oncology Group Study.[J]Investigational New Drugs.2003August;21(3):373-377.
194.Hu L,Mills GB,Mills GB,et al.In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor(LY294002).[J]Clinical Cancer Research.2006;6(3):880-886.
195.Sewell JM,Ritchie A,Ritchie A,et al.Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839("Iressa").[J]Br J Cancer.2002 86:456-462.
196.Russell J.Schilder,Michael W.Sill,Xiaowei Chen,et al.Phase Ⅱ Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression:A Gynecologic Oncology Group Study.[J]Clinical Cancer Research Vol.11,5539-5548,August 1,2005.
197.Wagner U,du Bois A,Pfisterer J,et al.Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase Ⅱ trial of the AGO Ovarian Cancer Study Group(AGO-OVAR 2.6).Gynecol Oncol.2007Apr;105(1):132-7.
198.Alberts.Liu,wilczynski,jang,et al.Phase Ⅱ trial of imatinib mesylate in recurrent,biomarker positive,ovarian cancer(Southwest Oncology Group Protocol S0211)[J]International Journal of Gynecological Cancer.August 2007;17(4):784-788(5).
199.D.Wright,A.Alvarezsecord,T.M.Numnum,et al.A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent,platinum-resistant ovarian cancer.[J]Journal of Clinical Oncology,2006 ASCO Annual Meeting Proceedings Part Ⅰ.Vol 24,No.18S(June 20 Supplement),2006:5019.200.Chura JC,Van Iseghem K,Downs LS Jr,et al.Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.Gynecol Oncol.2007 Nov;107(2):326-30.Epub 2007 Aug 15.
201.Hirte H,Vergote IB,Jeffrey JR,et al.A phase Ⅲ randomized trial of BAY 12-9566(tanomastat)as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy:a National Cancer Institute of Canada Clinical Trials Group Study.Gynecol Oncol.2006 Aug;102(2):300-8.
202.Michael J,Mohammad A,Anil K,et al.Ovarian Cancer p53 Mutation Is Associated with Tumor Microvessel Density.[J]Gynecologic Oncology.July 2002;86(1):85-90.
203.Zhang T,Guan M,Jin HY,etc.Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.Gynecol Oncol,2005,97(2):501-507
204.Thomas G,Robert F,Abbas Abdollahi,etc.The biology of ovarian cancer.Fox Chase Cancer Center 2001 Scientific Report.
205.Tanyi JL,Lapushin R,Eder A,etc.Identification of tissue-and cancer-selective promoters for the introduction of genes into human ovarian cancer cells.Gynecol Oncol,2002,85(3):451-458.
206.Kong BH,Song Y,Ma DK,etc.In vitro treatment of ovarian cancer cells with cytonine dearnases-thymidine kinase fusion disuicide gene therapy system under the control og human telommase reverse transcriptase gene promoter.Zhonghua Fu Chan Ke Za Zhi,2004,39(6):390-395.
207.Wen SF,Mc Donald,et al.Mevelopment and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.[J]Cancer Gene Ther.2000;7:1469-1480.
208.Alvarez RD,Gomez-Navarroj,Wang M,etc.Adenoviralmediated suicide gene therapy for ovariancancer[J].Mol Ther,2000,2(15):524-530.
209.Hook M,Irimutra T,Nicolson GL,A heparin sulfate-dagrading endogly considass from rat liver tissueo[J]Biochem Biophys Res Commun.1975,67:1422.
210.Vlodavsky I,Friedmarm Y,Elkin M,et al.Mammalian heparanase:gene cloning,expression an d function in tumor progression and metastasis.Nat Med,1999,5(7):793-802.
211.Hulett MD,Freenmn C,HamdoH BJ,et al.Cloning of mammalian heparanase,an importan t enzyme in tumor invasion an d metastasis,Nat Med,1999,5(7):803-809.
212.Fairbanks MB,Mildner AM,Leone jw,et al.Processing of thehuman heparan ase precursor an d evidence that the active enzyrne is a heterodimer.J BiOl Chem,1999,274(42):29587.29590.
213.Gohji K,Katsuoka Y,Okamoto M,et al.Human heparanase:roles in invasion and metastasis of cancer[J].Hinyokika Kiyo,2000,46(10):757-762
214.Vaday GG,Lider O.Extraeellular matrix moieties,cytokines,and enzymes dynamic effects on immune cell behavior and in--flammation.[J]LeukBiol.2000.67(2):149-158.
215.Eccles SA.Heparanase:breaking down barriers in tumors.[J]Nat Med,1999;5(7):735-736.
216.Gilat D,Hershkoviz R,Goldkorn I,et al.Molecular behavior dapts to context:heparanase functions as fin extracellular matrixdegrading enzyme or as fl T cell adhesion molecule,depending onthe local pH.[J],.J Exp Med,1995,181(5):1929.
217.Ihrcke NS,Reissner KJ,Reissner KJ,et al.Regulation of platelet heparanase during inflammation:role of pH and proteinases.[J]Journal of Cellular Physiology.1998;175:255-267.
218.Vlodavsky I,Friedman Y.Molecular properties and involvement of heparanase in cancer metastasis and mlgiogenesis[J].J Clin Invest.2001.108:341
219.Eccles SA.Heparanase:breaking down barriers in tumors[J].Nat Med,1999,5(7);735.
220.Pillarisetti S.lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan)and atherogenicity[J].Trends Cardiovasc Med,2000,10(2):60-65.
221.Marchetti D,Li J,Shen R.Astrocytes contribute to the brain metastatic specificity of melanoma cells by producing heparanase.Cancer Res,2000,60(17):4767-4770.
222.Sasaki M,Ito T.Erythromycin and clarithromycin modulation of growth factor-induced expression of heparan ase mRNA on human lung cancer ceils in vitro[J].Mediators Inflamm,2001,1of5):259.
223.Walch ET,Marchetti D.Role of neurotrophins and neurotrophins receptors in the in vitro invasion and heparanase production of human prostate cancer cells[J].Clin Exp Metastasis,1999,17(4):307.
224.Shteper P J,Zcharia E,Ashhab Y,et al.Role of promoter methylation in regulation of the mammalian heparanase gene.Oncogene,2003,22(49):7737-7749.
225.Oqishima T,Breault JE,Breault JE,et al.Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer.[J]Oncogene.2005;78(5):667-674.
226.de MestreA M,KhachigianLM,Santiago F S,et al.Regu lation of inducible heparanase gene tran scription in activated T cells by early growth response[J]Biol Chem,2003,278(50):50377-50385.
227.Ogishima T,Shiina H,Breault J E,et al.Increased heparanase expression is caused by promoter hypomethylation an dup-regu lation of transcriptional factor early growt h response.[J]irIham anprostate cancer.ClinCancerRes,2005,11(3):1028-1036.
228.Irit Cohen,Bella Maly,Itamar Simon,et al.Tamoxifen Induces Heparanase Expression in Estrogen Receptor-Positive Breast Cancer.[J]Clinical CancerResearch.2007.July 15;3:4069-4077.
229.Gingis-Velitski S,Zetser A,Kaplan V,et ol.Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans.[J]BiolChem,2004,279(42):44084-44092.
230.Michael Elkin,Irit Cohen,Eyal Zcharia,et al.Regulation of Heparanase Gene Expression by Estrogen in Breast Cancer.Cancer Research 63,8821-8826,December 15,2003.
231.Goldshmidt O,Zcharia E,Cohen M,etc.Heparanase mediates cell adhesion independent of its enzymatic activity.FASEB J,2003,17(9):1015-1025.
232.Friedmann Y,Vlodavsky I,Aingorn H,et al.Expression ofheparanase in normal, dysplastic and neoplastic humancolon mucosaalld stroma[j].Am JPathol,2000,157:1167.
233.Osama N,El-Assal Akira Yamanoi,Takashi Ono,et al.The Clinicopathological Significance of Heparanase and Basic Fibroblast Growth Factor Expressions in Hepatocellular Carcinoma.Clinical Cancer Research Vol.7,1299-1305,May 2001.
234.Alexander Koliopanos,Helmut Friess,Jorg Kleeff,et al.Heparanase Expression in Primary and Metastatic Pancreatic Cancer.Cancer Research 61,4655-4659,June 15,2001.
235.王辉,王谦。宫颈癌组织中乙酰肝素酶表达的临床研究。黑龙江医学。2007年04期。
236.Vlodavsky I,Zcharia E,Goldshmidt O,etc.Involvement of heparanase in tumor progression and normal differentiation.Pathoph3 siol Haemost Thromb,2003;3:[Suppll]:59-61.
237.崔红梅,王海琳,乙酰肝素酶在妇科肿瘤中的研究进展,国外医学妇产科学分册,2005,32(6):371-373。
238.ParishCR,Freeman C,Brown KJ,,et al.dentification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.Cancer Res,1999;59(14):3433-3441.
239.Kodama J,Hashen G,Hashen GH,et al.eparanase messenger RNA expression in epithelial ovarian tumor.[J]Int J Mol Med.2003;12(6):961-964.
240.Davidson B,Shafat I,Risberg B,etc.Heparanase expression correlates with poor survival in metastatic ovarian carcinoma.Gynecol Oncol.2007 Feb;104(2):311-9.Epub 2006 Oct 9.
241.毛敬,辛晓燕,刘玉等,卵巢癌uPA及HPA的表达与肿瘤转移的相关性研究,现代肿瘤医学,2006,3,14(3):329-331.
242.韦露薇,李力。乙酰肝素酶与卵巢癌浸润转移关系的相关研究。2008年3月硕士学位论文。
243.黄庆,田辉,李林等,乙酰肝素酶与肿瘤关系的研究进展,现代诊断与治疗,2006,5,17(3):160-163
244.Ginath S,Menezer J,Friedmann Y,et al..Expression of heparanase,Mdm2,and erbB2in ovarian cancerolnt J Oncol,2001,18(6):1133-1144.
245.韩静,杨鹰,阎萍等,乙酰肝素酶在卵巢癌组织中的表达及其临意义,第三军医大 学学报,2006,10,28(20),2054-2056.
246.苍亚芹,马致南。乙酰肝素酶在卵巢癌中表达的临床意义。黑龙江医学2007年05期。
247.Folkman J.Control of angiogenesis by heparin and other sulfated polysaccharides Advance in Experimental.[J]Medicine and Biology.1992;313:355-364.
248.Mesiano S,Jaffe RB,Jaffe RB,Role of vascular endothelial growth factor in ovarian cancer:inhibition of ascites formation by immunoneutralization[J]American Journal Of Pathology.1998;153:1249.
249.E S Bamberger and C W PerrettAngiogenesis in epithelian ovarian cancer.[J]Molecular Pathology;2002;55:348-359.,
250.Masatsugu Ueda,Yao-Ching Hung,Yoshito Terai,et al.Vascular Endothelial Growth Factor-C Expression and Invasive Phenotype in Ovarian Carcinomas[J]Clinical Cancer Research Vol.11,3225-3232,May 1,2005.
251.杨鹰,韩静,阎萍等,乙酰肝素酶在卵巢癌中的表达及其与肿瘤血管生成的关系。重庆医学。2006年24期。
252.Mohler JL,Partin AW,Isaacs JT,Coffey DS(1988)Metastatic potential prediction by a visual grading system of cell motility:prospective validation in the Dunning R-3327 prostatic adenocarcinoma model.Cancer Res 48:4312-4317.
253.A Ayhan,M Gultekin,C Taskiran,et al.Ascites and epithelial ovarian cancers:a reappraisal with respect to different aspects.[J]Int J Gynecol Cancer,January 1,2007;17(1):68-75.
254.Toh Y,Pencil SD,Nicolson GL.et al.A novel candidate metastasis-associated gene,mtal,differentially expressed in highly metastatic mammary adenocarcinoma cell lines.cDNA cloning,expression,and protein analyses.The Journal of biological chemistry.1994;269(37):22958-22963.
255.Wiemik PH,Schwartz EL,Strauman JJ.et al.Phase I clinical and pharmacokinetic study oftaxol[J].Cancer Res,1987,47(12):2486-2493.
256.Hollingsworth HC,Kohn EC,Steinberg SM,et al.Tumor angiogenesis in advanced stage ovarian carcinomas.Am J Pathol,1995,147(1):33- 41
257.李劲涛,杨 军,张秀丽等。RNAi最新研究概况。[J]细胞与分子免疫学杂志2007, 23(11):1077-1079.
258.Bustin SA.Absolute quantification of mRNA using realtime reverse transcription polymerase chain reaction assays[J].Mol Endocrinol,2000,25:169.
259.汪洋,宫琳琳,邵淑娟。实时荧光定量PCR在肿瘤研究中的应用。[J]肿瘤2004,24(2):196-198.
260.Orit Goldshrnidt,Eyal Zcharia,Miriam Cohen,et al.Heparanase mediates cell adhesion independent of its enzymatic activity.The FASEB Journal.2003;17:1015-1025.
261.Evgeny Edovitsky,Michael Elkin,Eyal Zcharia,et al.Heparanase Gene Silencing,Tumor Invasiveness,Angiogenesis,and Metastasis.JNCI Journal of the National Cancer Institute 2004 96(16):1219-1230.
262.Anna Zetser,Yulia Bashenko,Hua-Quan Miao,et al.Heparanase Affects Adhesive and Tumorigenic Potential of Human Glioma Cells[J]Cancer Research 63,7733-7741,November 15,2003.
263.L.Kjellen andU.Lindahl.Proteoglycans:Structures and interactions.Annu.Rev.Biochem.1990;60:443-475.
264.M.Bernfield,M.Gotte,P.W.Park,et al.Functions of cell surface heparan sulfate proteoglycans.Annu.Rev.Biochem.1999;68:729-777.